Part of Intestine	Control group	Pomegranate treated group	Sodium.butyrate treated group

Non-everted (μg)	Everted (μg)	Non-everted (μg)	Everted (μg)	Non-everted (μg)	Everted (μg)

Duodenum	12.4±0.14	13.1±0.2	7.07± 1.0	12.29±0 .7	11.9±1.0 †	15.5±0.3

Jejunum	13.3±0.66	15.2±0.2	8.96±0 .32	11.87±0.3	13.4±0 .4†	14.3±0.3

Ileum	9.97±0.77	17.1±0.3	7.97±0.05	14.82 ±0.4	10.3±0.8	16.8±0.8†

Colon	9.57±0.48	14.0±0.2	6.85±0.7	9.89±0.1	9.7±1.2†	14.5±0.3†


	Discharged	Expired

	32	18

Tracheostomy	26.5	23.5

	1.141	1.30

	21	29

Non Tracheostomy	26.5	23.5

	1.141	1.30


 	BRCA1	BRCA2	Non-BRCA1/2

All males in kConFab registry	429	339	19137

Breast Cancers	5 (1.2%)	35 (10.3%)	78 (0.4%)

Pathology Available	3	25	32


Patients with HPA	Gender	Age	Mechanism of trauma	Liver injury grade*	Symptoms of HPA	Blood transfusion

1	Female	25	Blunt	2	No	No

2	Male	20	Blunt	2	Yes	Yes

3	Male	45	Blunt	2	No	No

4	Male	9	Blunt	3	No	No

5	Male	30	Blunt	3	Yes	Yes

6	Female	42	Blunt	4	No	No

7	Male	42	Blunt	4	No	No


Age groups of Males/females 	Quantity of interviewees

50-60 (10 males)	10

63-69 (20 males/5 females)	25

70-75 (10 male hakims/7 females)	17

75-80 (8 female)	8


Branch and Terminal Node Number and Description	N	AT%	Mean Distance

Node	Suburban branch

1.	Front porch > 0.83, driveways < 0.83, sidewalks > 0.67	136	7 4,8,9,11,12	1366.45 2,4–12

2.	Blank walls > 0.26, front porch < 0.83, driveways < 0.83, sidewalks > 0.67	39	23 8,9,11,12	688.55 1,4,5,11,12

3.	Blank walls < 0.26, front porch < 0.83, driveways < 0.83, sidewalks > 0.67	8	75	1245.7412

	Urban branch

4.	Zebra crosswalks < 0.03, driveways > 0.83, sidewalks > 0.67	137	23 1,8,9,11,12	1123.83 1,2,6–12

5.	Traffic/pedestrian signals > 0.44, zebra crosswalks > 0.03, driveways > 0.83, sidewalks > 0.67	60	25 8,9,11,12	1105.56 1,2,6–12

6.	Curb cut < 0.91, decorative sidewalks > 0.21, zebra crosswalks > 0.03, driveways > 0.83, sidewalks > 0.67	31	29 9,11,12	464.75 1,4,5,7,8,10,12

7.	Sidewalk buffer > 0.93, curb cut > 0.91, decorative sidewalks > 0.21, traffic/pedestrian signals < 0.44, zebra crosswalks > 0.03, driveways > 0.83, sidewalks > 0.67	24	42 1,2	739.21 1,4–6,9,11,12

8.	Sidewalk buffer < 0.93, curb cut > 0.91, decorative sidewalks > 0.21, traffic/pedestrian signals < 0.44, zebra crosswalks > 0.03, driveways > 0.83, sidewalks > 0.67	14	79 1,2,4,5	739.6 1,4–6,9,11,12

9.	Decorative sidewalks < 0.21, traffic/pedestrian signals < 0.44, zebra crosswalks > 0.03, driveways > 0.83, sidewalks > 0.67	26	77 1,2,4–6	401.25 1,4,5,7,8,10,12

	Alley branch

10.	Crosswalks < 0.14, convenient to cross segment < 0.15, sidewalks > 0.67	18	39 1,2	774.1 1,4–6,9,11,12

11.	Crosswalks > 0.14, convenient to cross segment < 0.15, sidewalks > 0.67	18	78 1,2,4–6	297.85 1,2,4,5,7,8,10

12.	Convenient to cross segment > 0.15, sidewalks < 0.67	25	100 4,8,9,11,12	137.18 1–10


# Gene ID Gene Description

AKAP11 A-kinase anchor protein 11 2

AKR1A1 alcohol dehydrogenase 3

ATP5O ATP synthase subunit O, mitochondrial precursor 4

C1orf109 hypothetical protein LOC54955 5

C2orf29 hypothetical protein LOC55571 6

C9orf123 transmembrane protein C9orf123 7

CDK9 cell division protein kinase 9 8

CHSY1 chondroitin sulfate synthase 1 9

CKAP2L cytoskeleton-associated protein 2-like 10

CLINT1 clathrin interactor 1 11

DUSP2 dual specificity protein phosphatase 2 12

DUSP6 dual specificity protein phosphatase 6 isoform 13

HSPC157 hypothetical LOC29092 14

KIAA0427 CBP80/20-dependent translation initiation factor 15

LDHA L-lactate dehydrogenase A chain isoform 5 16

LOC100188949 hypothetical LOC100188949 17

LOC285456 hypothetical LOC285456 18

LSM14B protein LSM14 homolog B 19

MAX protein max isoform a 20

MRPS18A 28S ribosomal protein S18a, mitochondrial 21

MTF2 metal-response element-binding transcription 22

NAIF1 nuclear apoptosis-inducing factor 1 23

NDUFA10 NADH dehydrogenase [ubiquinone] 1 alpha 24

POMP proteasome maturation protein 25

PSMA6 proteasome subunit alpha type-6 26

RBM16 putative RNA-binding protein 16 27

RBM38 RNA-binding protein 38 isoform a 28

RPN1 dolichyl-diphosphooligosaccharide--protein 29

SEPHS2 selenide, water dikinase 2 30

SIRPG signal-regulatory protein gamma isoform 1 31

SPRED2 sprouty-related, EVH1 domain-containing protein 32

TFRC transferrin receptor protein 1 33

TMEM18 transmembrane protein 18 34

TRIP13 thyroid receptor-interacting protein 13 isoform 35

TXN2 thioredoxin, mitochondrial precursor 36

UBE2D2 ubiquitin-conjugating enzyme E2 D2 isoform 1 37

ZFAT zinc finger protein ZFAT isoform 1 38

ZNF212 zinc finger protein 212 39

ZNF683 zinc finger protein 683


Part	Number of sub-parts	Number of guidance points

Leadership	8	93

Policy and strategy	5	43

People management	6	60

Resources	7	54

Processes	4	29

Customer and society results	2	43

People results	2	36

Contractor results	2	33

Key performance results	2	19

Total	38	410


	Nutridrink	Impact	Return to Nutridrink	p

Body weight (kg)	57 ± 5.8	57 ± 5.9	58 ± 5.8	NS

Systolic BP (mmHg)	115 ± 11	110 ± 7	117 ± 11	0.012

Diastolic BP (mmHg)	69 ± 9	64 ± 8	69 ± 9	0.03

Heart rate (pulse/min)	88 ± 15	77 ± 17	80 ± 14	0.002

BMI (kg/m2)	18.8 ± 1.7	18.9 ± 1.6	19 ± 1.6	NS


Independent variables 	Model 1	Model 2	Model 3

Health-related risk factors

 Medical conditions (index)	−0.134***	−0.052***	−0.036*

 Mobility difficulties (index)	−0.273***	−0.115***	−0.079***

 Activity limitations (index)	−0.504***	−0.196***	−0.168***

Sociodemographic variables

 Age (cont.)	 	 	−0.104***

 Language: Swedish (ref. Finnish and others)	 	 	0.068***

 Gender: female (ref. male)	 	 	0.056***

 Civil status: partnership (ref. single)	 	 	0.052***

 Income: high (ref. low)	 	 	0.062***

 Education: high (ref. low education)	 	 	0.083***

 Country: Sweden (ref. Finland)	 	 	−0.015

n	 	5435	5435

Adjusted R square	 	0.071	0.101


Test Type	5-Option Version (n = 25)	2-Option Version (n = 37)

	Without OPC	With OPC*	Without OPC	With OPC**

FOBT	21%	17%	32%	54%

Sigmoidoscopy	4%	8%	-	-

FOBT & Sigmoidoscopy	21%	21%	-	-

Colonoscopy	46%	42%	68%	41%

Barium Enema	4%	8%	-	-

No Screening	4%	4%	-	5%


Time from onset of illness 	Signs/symptoms	Drug exposure 	Laboratory values

ALT	ALP	Total bilirubin	Direct bilirubin	Misc.

−5	Sore throat	Amoxicillin started

0	Fever, anorexia, dysphagia, neck swelling, and cervical lymphadenopathy	Ceftriaxone and vancomycin started

3–5	Worsening of neck swelling	Ceftriaxone and vancomycin discontinued, and ampicillin/sulbactam and steroid started

5–10	Diarrhea	Ampicillin/sulbactam and steroid discontinued, and clindamycin and probiotics started

10	Fever, headache, dizziness, chest pain on coughing, and dark urine. Hepatosplenomegaly, RUQ tenderness	Clindamycin switched to ampicillin/sulbactam	406	404	3.0	2.7

16–23	Generalized maculopapular rash and pruritus 	Ampicillin/sulbactam	152	737	8.8

25–30	Abdominal pain, vomiting. Hepatomegaly	Ampicillin/sulbactam	124	780	9.9	 	AST 130

48	Chest pain, fatigue, pruritus, acholic stools, and jaundice	 	138	713	13.4	8.8	Cholesterol 1044, GGT 347,

53	Increasing pruritus, anorexia	 	117	651	12.7	8.5	GGT 294

67	Anorexia, pruritus	 	48	493	12.6	8.7	GGT 77

83	Anorexia	 	83	497	8.3	5.5	GGT 273

111	No anorexia	 	51	670	2.3	1.2	GGT 507


Inclusion criteria	Exclusion criteria

Original research articles referring to noninvasive modalities or minimally invasive techniques to accelerate orthodontic tooth movementAnimal studies	Randomized clinical trialsArticles dealing with highly invasive proceduresArticles referring to use of biochemical or drugs to accelerate tooth movementMicroimplants or frictionless brackets as a modality to reduce treatment duration Reviews, interviews, and discussions


Area	Parameter estimate (SE)	t‐Value (P‐value) for parameter difference from zero	t‐Values (P‐values) for differences of least squares means

Garbage	Light	Lawn	Other modified	Natural

Garbage	2.92 (0.52)	5.61 (<0.0001)		2.66 (0.08)	4.34 (<0.01)b	4.11 (<0.01)b	5.61 (<0.0001)b

Under lights	1.47 (0.60)	2.46 (0.01)			0.96 (0.87)	1.37 (0.65)	2.46 (0.12)

Lawn	0.89 (0.58)	1.54 (0.13)				0.48 (0.99)	1.54 (0.54)

Other modified	0.60 (0.63)	0.94 (0.35)					0.94 (0.88)

Natural	0a


Locus	Primer sequences (5′–3′)	Primer sequences (5′–3′)

b50	F: AACAATCCAGGAGTGGCAATC	R: ACAAGCGAAGATCGTCTCATC

b35	F: CGTTCAGTCACCAGCAAGG	R: GAGGGAAGCAGGGAGAGC

b38	F: TAATCCCTCAATGGCTCTTTTC	R: GAGAAGGATACGAATTGACAGG

b40	F:TGTATAGAACTGAGTAAATGATTG	R: CAACTTTCTTAAACCACTTTCG

b43	F: CGAGCCTTCTTCTTCTTCTGG	R: GCAAGCAATACGGACAGTAGG

c03	F:CGTGAAAATAGTGATATGTGTG	R: ACTGTAACAATCAAGAAGAAACC

c07	F:GCCACAGCCGAGGAAGAG	R: TCTCATCACCACCACCTTAGG

b27	F: AGCCAGGTTCCAGAAGTCC	R: CATAATCACAAAGTCTCGGTTCC

b28	F: TCCCACCACGGACTACTG	R: AACCACCATCATCATCATCATC

b11	F: GCGGAGGCTTAATTTGCTTTG	R: ACTCAATACATACACGGCACTAG

b16	F: ACCTCTACGGACCTCTTCTTC	R: CATAACATAACATGACACACAAGC

b24	F: GAGCCAGAGCCAGGTTCC	R: ACAAAGTCTCGGTTCCTTACAC

b34	AATAGAATGTGGAGGCGATAGAG	R: AAACCATAAATCAACTACCGAACC

b64	F: CTTGAGATACAGCCTTCCATTAG	R: CACACCTCGCTTCCCTTG

c17	F:GAAACTATTTCCACCAACAAAG	R: ACACACATTCCTACACACC

b57	F: CGGATATGGTGGAGGTTATGC	R: CAGAACGACGACGACGAC

b65	F: ACGAACCACAACACAGAGAG	R: ACGAGGGAACACCAGAGAG

c18	F:AAGCCGAGCGTGAAGAAG	R: ACACACAGAAAGAACACAAGAC

b53	F: GGCTCAAGTTTGCTCATAGATTC	R: CGGCTTCGCTTTAGGATTTG

b56	F: CGGTCTGTGGATACGAATGG	R: GACGACGACGACGATGATG

c10	F:AGTGCGGAGATAACTGTTC	R: GGCTACTTTATTCTAAACCAAAC


Second-level category	n (%)

b140 attention functions	149 (85)

b130 energy and drive functions	127 (73)

b147 psychomotor functions	124 (71)

b760 control of voluntary movement functions	114 (65)

b164 higher-level cognitive functions	106 (61)

b152 emotional functions	90 (51)

b126 temperament and personality functions	64 (37)

b125 dispositions and intra-personal functions	58 (33)

b144 memory functions	55 (31)

b117 intellectual functions	31 (18)

b156 perceptual functions	31 (18)

b134 sleep functions	30 (17)

b180 experience of self and time functions	26 (15)

b235 vestibular functions	19 (11)

b735 muscle tone functions	15 (9)

b260 proprioceptive functions	14 (8)

b160 thought functions	12 (7)

b210 seeing functions	12 (7)

b230 hearing functions	11 (6)

b110 consciousness functions	10 (6)

b122 global psychosocial functions	10 (6)

b163 basic cognitive functions	10 (6)

b114 orientation functions	9 (5)

b167 mental functions of language	9 (5)

b280 sensation of pain	9 (5)

b330 fluency and rhythm of speech functions	9 (5)

b765 involuntary movement functions	9 (5)

b176 mental function of sequencing complex movements	8 (5)

b265 touch function	8 (5)

b270 sensory functions related to temperature and other stimuli	8 (5)


	Total number	Gleason grade group 1	Gleason grade group 2	Gleason grade group 3	Gleason grade group 4	Gleason grade group 5

N° of primary tumors	60	12	12	12	12	12

N° of CD44v8-10	24	3	3	5	6	5

% positive tumors	40%	25%	25%	42%	50%	42%


 	Boys	Girls

 	Verbal abuse	Threat of violence	Physical assault	Verbal abuse	Threat of violence	Physical assault

Verbal abuse	1.00	 	 	1.00

Threat of violence	0.35*	1.00	 	0.34*	1.00

Physical assault	0.27*	0.52*	1.00	0.23*	0.36*	1.00


 	Clinical setting

Barrier	HTN & eGFR ≥ 60 (%)	HTN & eGFR < 60 (%)

No impact on management	37	24

Limited time/more urgent patient issues	25	20

Not recommended by guidelines	25	11

Cost	13	9

Poor patient adherence	5	5


Progression to PID	Fraction progressing, % (95% CI)*	Cumulative incidence of PID after one year, % (95% CI)†	Akaike’s Information Criterion‡

Control group	Intervention group

Data

Results from RCT	 	1.9 (1.2 to 2.9)	1.3 (0.7 to 2.1)

Model

Immediate progression	8.3 (5.7 to 11.0)	1.6 (1.1 to 2.1)	1.6 (1.1 to 2.1)	13.3

Constant progression	9.9 (6.8 to 13.0)	1.7 (1.2 to 2.3)	1.5 (1.0 to 1.9)	12.1

Progression at the end	10.0 (6.8 to 13.1)	1.7 (1.2 to 2.3)	1.5 (1.0 to 1.9)	12.1


 	Pharmacologic intervention title: ‘Vitamins C and E for prevention of pre-eclampsia in women with type 1 diabetes (DAPIT): a randomized placebo-controlled trial’ [28]	Non-pharmacologic intervention title: ‘Treatment of childhood obesity by retraining eating behaviour: randomized controlled trial’ [29]

Active ingredients	Vitamins C and E	Not reported

Comparator	Placebo	Not reported

Health condition	Pre-eclampsia	Obesity

Eligibility criteria	Women with type 1 diabetes	Children

Objective	Prevention of pre-eclampsia	Retraining eating behaviour

Trial design	Randomized controlled trial	Randomized controlled trial


Matrix Mechanical Characteristics that Impact Cell or Tissue Function

• Pore size and morphology (Chan et al., 2008); [142]

• Elasticity (Janson et al., 2015); [131]

• Stiffness (Xia et al., 2017); [143]

• Hydration degree (Wu et al., 2006); [140]


Name	SNP	Primer	Product length (bp)	Primer sequence (5’→3’)

rs17576	A/G	Forward		CAATTCACCCTCCCGCACTC

		Reverse	222	GGAAGATGAATGGAAACTGG

rs2250889	C/G	Forward		GTATTTGTTCAAGGATGGGTG

		Reverse	367	AGACGTTTCGTGGGTTAT


Material	Tested	Ref.

Boron nitride, BN	Tested, in use, high efficiency, low erosion (0.02 mm3/C at 300 V)	131, 139, 140

Borosil, BN + SiO2	Tested, in use, high efficiency, low wear	131, 141

Alumina, Al2O3	Tested, medium efficiency, low erosion (0.01 mm3/C at 300 V)	139, 141

Silicon carbide, SiC	Tested, medium efficiency, medium erosion	131

Graphite	Tested, low efficiency, high erosion	65

Nanocrystalline diamond	Tested, high efficiency, low erosion	131, 142

CVD diamond	Tested for wear, lower erosion	63

Ultra-BN, uBN	Tested, high efficiency, very low wear	New result


 	HAZ	WAZ

 	Coefficient	Percent of ∆	Coefficient	Percent of ∆

Raw gap, ∆	.379	100.00	.248	100.00

Of which:

 Explained	.234	61.7	.164	66.3

 Unexplained	.145	38.3	.083	33.7


Sub-scale	Attitudinal items	Surgeon (n=41)	Anaesthetist (n= 33)	Nurse (n=33)

 	 	Mode	IQR	Mode	IQR	Mode	IQR

 	There is little difference between the surgical checklist at GUH and the WHO surgical checklist.	3	2	1	3.25	2	2.75

Norms	The complete checklist is used for every procedure in every theatre at UHG.	2	3	1	3	5	1

 	The complete checklist is used for every procedure in which I am involved in theatre.	5	1.5	1	3	5	1

 	When the checklist is being carried out, everyone in theatre stops what they are doing and listens until it is completed.	1	3	1	1	1	1.5

 	Sometimes sections of the checklist are not completed.*	4	2	4	2	4	1

 	The individual who signs the checklist personally ensures that the relevant steps have been completed.	5	1.5	4	2	4	1

Impact on teamwork & safety	I believe that failing to use the checklist is poor professional practice.	5	1	5	1	5	0

 	I believe using the checklist reduces the likelihood of human error.	5	0.75	5	1	5	0

 	I believe using the checklist improves patient safety.	5	0.5	5	1	5	0

 	I believe using the checklist improves teamwork in theatre.	5	1	5	1	5	1

 	The use of the checklist should be mandatory for every case.	5	1	5	1	5	0

Support	Surgical personnel support the use of the checklist.	5	1	4	1	5	5

 	Anaesthetic personnel support the use of the checklist.	4	2	4	1	5	4

 	Nursing staff support the use of the checklist.	5	0	4	1	5	5

 	Senior theatre personnel support the use of the checklist.	5	2	4	1	5	5

 	Junior theatre personnel support the use of the checklist.	5	1	4	1	5	5

 	Management support the use of the checklist.	5	2	5	1	5	5

Initiate	I have initiated the use of the checklist in the past.	5	2	1	3	5	0

 	I intend to initiate the use of the checklist in the future.	5	1	3	1.75	5	0

Barriers	The requirement for signatures.	4	2.5	5	3	5	1

 	Lack of assertiveness of staff.	4	2	4	2.5	4	1

 	Lack of time.	4	2	4	2.75	4	1

 	Lack of training.	4	2	4	2	4	1.5

 	The lack of an electronic version of the checklist.	3	2	5	3	3	2


Research problem	Tool/Instrument	Authors

Nausea and vomiting	Nausea Vomiting Pregnancy QOL (NVP QOL)	[8] Canada

Pregnancy Unique Questionnaire Emesis (PUQE)	[9] Canada, [10] Canada

McGill nausea questionnaire	[11] Canada

Rhodes’ scores (RI)	[12] Canada

Short form – 36 (SF-36)	[13] China

SF-12, NVP specific QOL	[14] Canada

NVPQOL, SF-36, SCL90	[15] USA

Irritable bladder	Incontinence Impact Questionnaire (IIQ), Urogenital Distress Inventory (UDI)	[6] Netherlands

Incontinence Questionnaire Short Form (ICIQ-SF)	[16] Turkey

Back pains	Nottingham Health Profile (NHP) Disability Rating Index (DRI)	[17] Sweden

Pregnancy Mobility Index (PMI)	[18] Netherlands

WHOQOL-BREF	[19] Turkey

Anxiety and depression	Finnish modification of SF of the beck depression inventory and anxiety	[20] Finland

Hospital Anxiety and Depression Scale (HADS)	[21] Sweden

EPDS, SF-36v2	[22] China

WHOQOL-BREF, EPDS	[23] Austria


Laboratory site	Samples (n)	Number of devices (n)	Runs per day (n)	Approximately overall time requirement

		Sprinter XL	EUROPattern	Screening	Titer

Houston, TX, USA	141	1	1	1	1	06:00 h

Tampa, FL, USA	134	1	1	1	1	06:10 h

Dallas, TX, USA	187	1	1	1	1	06:40 h

Phoenix, AZ, USA	231	1	1	1	1	07:10 h

Birmingham, AL, USA	236	2	2	2	1	06:30 h

Burlington, NC, USA	471	2	2	2	2	07:10 h

Dublin, OH, USA	330	2	2	2	2	07:10 h

Raritan, NJ, USA	568	3	3	3	3	07:05 h


Characteristic	β	Standard error	P

Baseline	-5.169	1.388	0.000

Proband breast cancer diagnosis ≤35 years	2.791	1.379	0.043

Proband breast cancer diagnosis 36-39 years	2.248	1.365	0.100

Proband breast cancer diagnosis 40-49 years	1.763	1.355	0.193

Proband breast cancer diagnosis 50-59 years	1.065	1.354	0.431

Proband bilateral breast cancer at any age	1.036	0.462	0.025

Proband ovarian cancer at any age	0.238	1.469	0.871

Proband triple-negative breast cancer at any age	1.323	0.331	0.000

For each relative with cancer:

 First degree, breast cancer diagnosis ≤39 years	0.950	0.369	0.010

 First degree, breast cancer diagnosis 40-49 years	1.450	0.386	0.000

 First degree, breast cancer diagnosis 50-59 years	1.445	0.450	0.001

 First degree, breast cancer diagnosis 60+ years	0.207	0.646	0.749

 First degree, ovarian cancer at any age	2.556	0.769	0.001

 Second degree, breast cancer diagnosis at any age	0.359	0.272	0.187

 Second degree, ovarian cancer diagnosis at any age	1.861	0.832	0.025


 	Normal thyroid (n.4)	Hyperplasia/Benign nodules (n.5)	Thyroid carcinoma (n.7)

Video intensity UCAIGg

Video intensity difference	11.3 (9.4-14.7)	12.2 (8.5-19.6)	19.4 (11.4-22.6)

Video intensity UCAVEGFR2

Video intensity difference	10.9 (10.3-14.9)	13.3 (10.8-15.8)	30.1 (25.1-35.6)* §


	Mechanism of action	Drugs	Trial (reference)	Study population	Benefits	Common severetoxicities

Apoptosis	PARP inhibitors	Olaparib	Phase II (127)	Recurrent/metastatic adult ES (failure to prior CH), n = 12 patients	NO responses SD: 4 patients, TTP: 5.7 weeks	No significant toxicities

	Heat shock protein inhibitors	Retaspimycin (Hsp-90 INH)	Phase I (128)	Metastatic and/or unresectable STS, n = 54 patients	PR: 2 patients (proof of clinical activity)	Grade 3–4:Fatigue Nausea and vomiting Headache Artharalgia

	Proteaseome inhibitor	Bortezomib	Phase II (129)	Metastatic OS, ES, RMS, and STS with no prior treatment for advanced disease, n = 25 patients	Lack of benefit (trial prematurely closed)	Grade 3–4:Neuropathy Asthenia Myalgias

	MDM2 inhibitor	RG7112	Proof of mechanism study (130)	WDLS or DDLS with MDM2 amplification receive RG7112 prior to surgery, n = 20 patients	SD: 14 patients, IHQ: activation of p53 pathway	Grade 3–4Neutropenia Thrombocytopenia

			Phase I (131)	Phase I trial with extension cohort for sarcoma patients, n = 30 (sarcoma patients)	Metabolic responses (PET-CT) IHQ: activation of p53 (MDM2-independent)	Grade 3–4 Cytopenias

	PI3K-AKT-mTOR pathway inhibitors	Ridaforolimus (mTOR INH)	Phase II (132)	Pre-treated advanced bone and STS, n = 212 patients	RR: 1.9%, clinical benefit: 28.8%	Grade 3–4Fatigue Stomatitis Hypertriglyceridemia Anemia Thrombocytopenia

			Phase III (133)	Advanced bone and STS with clinical benefit to previous CH were randomized to maintenance Ridaforolimus or Placebo, n = 711 patients	Improvement in PFS (17.7 weeks with Ridaforolimus vs. 14.6 weeks with Placebo, HR: 0.72, p: 0.001)	Similar to previous study

		Everolimus (mTOR INH)	Phase II (134)	Pre-treated advanced bone and STS, n = 41 patients	Poor clinical activity	Grade 3–4Hyperglicemia Stomatitis Pain Asthenia

	Anti-angiogenic therapy	Sorafenib (VEGFR2, VEGFR3, PDGFR, and c-Kit INH)	Phase II (135)	Pre-treated advanced STS, n = 101 patients	RR: 14.5%, SD: 32.9% (leiomyosarcoma better PFS)	Grade 3–4Fatigue Diarrhea Hand–foot Syndrome Nausea and vomiting

		Pazopanib (VEGFR-1, VEGFR-2, VEGFR-3, PDGFR, and c-Kit INH)	Phase III (136)	Pre-treated non-adipocytic STS randomized to PAZOPANIB vs. PLACEBO, n = 369 patients	Improvement in PFS (4.6 months with PAZOPANIB vs. 1.6 months with Placebo, HR: 0.31, p < 0.0001)	Grade 3–4Asthenia Hypertension Anorexia Alteration of transaminases

Mitotic catastrophe	CDK inhibitors	Palbociclib (CDK4 and CDK6 INH)	Phase II (137)	WDLS or DDLS with CDK4 amplification and pRb expression	66% of patients free of PD at 12 weeks	Grade 3–4Anemia Neutropenia Thrombocytopenia


	Flg22-responsive genes*	Light-responsive genes**	Overlap genes	P-value***

Flg22-induced light-dependent genes	3579	(flg22-up)	2576	(light-dependent)	536	8.790e-24

Flg22-induced light-repressed genes	3579	(flg22-up)	2161	(light-repressed)	239	1.084e-05

Flg22-repressed light-dependent genes	4159	(flg22-down)	2576	(light-dependent)	359	2.599e-04

Flg22-repressed light-repressed genes	4159	(flg22-down)	2161	(light-repressed)	370	0.15


Patient No.	Ethnicity	Biochemical findings	Phenotype	ACADS genotype

C4a	C4/C2a	C4/C3a	C4/C8a	EMAb

1	R	1.53	0.21	1.35	40.38	N/A	microcephaly, DD/ID, marked hypotonus, horizontal nystagmus	c.310_312delGAG/c.310_312delGAG

9	R	N/A	N/A	N/A	N/A	634	DD/ID, apnoic pause, bleeding into the adrenal glands in the neonatal age, hypoglycaemia

10	R	1.44	0.05	0.81	30.64	363	central hypotonus with acral hypertonus, laryngomalatia

12	R	1.07	0.07	1.07	40.75	146	epilepsy, hypotonus, irritability, cerebral palsy, pectus carinatum, kyphoscoliosis

14	R	0.97	0.08	0.61	59.6	1070	recurrent sepsis, MAC, hepatosplenomegaly, severe hepatopathy along with gastroenteritis

15	C	2.77	0.11	3.26	60.23	169	mild MAC in neonatal age, at age 2 yo - DD/ID, hypotonus, at age 3 yo – without DD/ID

17	R	N/A	N/A	N/A	N/A	329	severe DD/ID, parents consanguinity, MAC, brother – DD/ID with no biochemical positivity to SCADD

23	R	1.19	0.07	0.57	129	322	hypoglycaemia, elevated CK

24	R	1.00	0.10	0.53	60.88	N/A	mild MAC

25	R	1.90	0.14	1.98	52.34	657	DD	c.310_312delGAG/c.1138C>T

32	R	N/A	N/A	N/A	N/A	306	prematurity, severe DD/ID, quadruparesis, recurrent hypoglycaemia

33	R	N/A	N/A	N/A	N/A	965	DD/ID(milder than brother - patient No. 32)

35	R	1.52	0.08	0.94	77.08	433	mild hepatomegaly, hyperammonemia, MAC

52	N/A	0.61	0.06	5.28	10.18	N/A	DD/ID c	c.310_312delGAG/c.625G>A

53	R	1.20	0.07	0.72	17.93	135	short stature, ophtalmoplegia (first sign – suspicion for congenital myasthenia), hypomimic facies, severe kyphoscoliosis, DD/ID, cachexia, hypotonus, respiratory failure, diffuse brain edema, coma vigile (high suspicion for other unknown neuromuscular disease)

54	R	N/A	N/A	N/A	N/A	71	epilepsy

55	R	0.44	0.03	0.19	50.42	54	recidivating granulomatous hepatopathy with hepatomegaly, mild hypertonus, mild DD/ID, epilepsy, apnoic pauses

56	R	0.86	0.03	0.41	21.15	110	recurrent seizures


GeneID	Gene Description	miRNAs	miRDB (target score)	TargetScan (Context + Percentile)

ABHD3	Abhydrolase domain containing 3	miR-1244, miR-130a, miR-205	74, > 85	84

CCNJ	Cyclin J	miR-205-5p	90	98

CHAMP1/ZNF828	Chromosome alignment maintaining phosphoprotein 1	miR-7-5p, miR-378a-3p	60-96	96

MYB	v-Myb myeloblastosis viral oncogene homolog (avian)	miR-15b-5p, miR-16-5p	74	96

PIK3CD	Phosphoinositide-3-kinase, catalytic, delta polypeptide	miR-7-5p	94	91

VEGFA	Vascular endothelial growth factor A	miR-205, miR-15b	79	97

FGD4	RhoGEF and PH domain containing 4	miR-17, miR-106a, miR-20a	100	98

SPOPL	Speckle-type POZ protein-like	miR-9-3p	97	97

RAB9B	RAB9B, member RAS oncogene family	miR-15b-5p, miR-16-5p, miR-130a-3P, miR-9-5p	67-86	67-86

EGFR	Epidermal growth factor receptor	miR-7	81	93

E2F1	E2F transcription factor 1	miR-205, miR-17, miR-20b	77	80

DOK4/IRS-5	Docking protein 4	miR-205	N/A	94


Diagnosis	n

Breast cancer	200

Glioma	144

Cervical carcinoma	117

Meningioma	72

Pituary adenoma	50

Cerebral lymphoma	49


	Food resource referrals - 2016

Pediatrics clinic	438

Internal medicine clinic	140

Family medicine clinic	246

Emergency department	55 (25 Attending Physicians, 22 Resident Physicians, 8 Physician Assistants)

Psychiatry clinic	52


Reference	Sample number	Histotype	Results

Sawabata et al. (17)	9	NSCLC	CTC-positive in 4/9 patients. No recurrence after surgery

Bevilacqua et al. (19)	5	SCLC	CTC have a role in SCLC patients diagnosis

Tanaka et al. (20)	150	NSCLC and SCLC	CTC well differentiate stage I from stage IV tumors

Hou et al. (21)	50	SCLC	CTCs ≥ 2 in 86%. Higher CTC number → shorter OS. CTC-positive decreased after CT (60%)

Naito et al. (22)	51	SCLC	CTCs detected in 68.6, 26.5, and 67.6% at B, post-CT, and R, respectively. CTCs > 8 → worse OS

Hiltermann et al. (23)	59	SCLC	Median CTCs at B = 6 and 63 in localized and metastatic disease, respectively. CTCs decrease after CT → strong predictor of OS

Normanno et al. (24)	60	SCLC	CTCs identified in 90% at B and associated to involved organs. CTC reduction higher than 89% after CT → better OS

Hou et al. (25)	97	SCLC	CTCs present in 85%. CTCs ≥ 50 at B → worse OS. Failure of CTC to decrease <50 after CT → worse prognosis

Krebs et al. (26)	101	NSCLC	CTC number at B higher in stage IV than stage III (60 and 27, respectively).CTCs number → prognostic factor for PFS and predictor of OS after first cycle of CT

Hirose et al. (27)	33	NSCLC	CTCs positive in 36.4 and 15.2% had five or more CTCs before CT. Positive CTCs patients → progressive disease

Punoose et al. (28)	41	NSCLC	CTCs identified in 78% at B. CTC decrease during CT → longer PFS

Muinelo-Romay et al. (29)	43	NSCLC	CTCs detected in 41.9%. CTCs ≥ 5 → shorter PFS and OS. CTC decrease after second cycle of CT → higher response and better PFS and OS

Isobe et al. (30)	24	NSCLC	CTCs detected in 33.3%. EGFR mutations in cfDNA: 25%. EGFR mutation rate in cfDNA higher when CTCs ≥ 2

Swennenhuis et al. (31)	10	NSCLC and SCLC	DNA isolation and sequencing from a single CTC


Antibiotic class	Multidrug-resistant (n = 226)	Non-multidrug-resistant (n = 514)	P-value

Aminoglycosides	226 (29.2%)	505 (91.1%)	<0.001

Antipseudomonal carbapenems	226 (15.0%)	508 (84.6%)	<0.001

Antipseudomonal cephalosporins	226 (26.5%)	504 (93.7%)	<0.001

Antipseudomonal fluoroquinolones	222 (21.5%)	502 (88.4%)	<0.001

Antipseudomonal penicillins +	221 (22.2%)	502 (89.0%)	<0.001

β-lactamase inhibitors

Monobactams	158 (13.9%)	208 (81.2%)	<0.001

Phosphonic acids	86 (40.7%)	105 (81.0%)	<0.001

Polymyxins	159 (97.5%)	215 (92.1%)	0.025


Variable	No. of missing data

Expenditure	2

Family support	2

MBI at admission	10

WHOQOL-BREF at admission	15

Number of joints with limited ROM at admission	50

MBI at discharge	8

WHOQOL-BREF at discharge	12

Number of joints with limited ROM at discharge	18

Work status after discharge	4


Name	Forward	Reverse	Accession number	Transcripts length (base pairs)	Primer efficiency (%)

Housekeeping gene study

 Actb	agccatgtacgtagccatcc	accctcatagatgggcacag	NM_031144.3	115	100.8

 Gapdh	gtgatgctggtgctgagta	gcggaaggggcggagatg	NM_017008.4	115	77.2

 Hmbs	aggatgggcaactgtacctg	aactgtgggtcatcctctgg	NM_013168.2	130	85.1

 Hprt1	gcagactttgctttccttgg	agaggtccttttcaccagca	NM_012583.2	79	86.3

 Ppia	catcctgaagcatacaggtc	catccagccactcagtctt	NM_017101.1	107	98.7

 Ppib	caagacctcctggctagacg	ttctccaccttccgtaccac	NM_022536.2	81	87.6

 Rpl13a	gatgaacaccaacccgtctc	atcccatccaacaccttgag	NM_173340.2	141	90.5

 Sdha	cgagatccgtgaaggaagag	ctctgagatcccaggcagac	NM_130428.1	109	90.0

Gene expression study

 Ppiba	caagacctcctggctagacg	ttctccaccttccgtaccac	NM_022536.2	81	98.9

 Rpl13aa	gatgaacaccaacccgtctc	atcccatccaacaccttgag	NM_173340.2	141	98.9

 Adamts4	aactccctgttccccagact	tagcttcagggccaggtaga	NM_023959.1	271	91.4

 Mmp9	cactgtaactgggggcaact	cacttcttgtcagcgtcgaa	NM_031055.1	150	103.8

 Plat	tctgccgcccactgctttg	cgaatgtctgctcctcctctcc	NM_013151.2	103	106.7

 Serpin1	atgaggctggtggcatctac	gatcagctgtggtttgagca	NM_053779.1	131	99.8

 Timp1	ggttccctggcataatctga	atggctgaacagggaaacac	NM_053819.1	99	101.2

 Timp3	gctgtgcaactttgtggaga	aattgcaacccaggtggtag	NM_012886.2	86	93.6


Primers	Sequences	Nucleotide position

	First round

Sense	5′-TTCATACAGTAACGCCCAGC-3′	259–278

Antisense	5′-GCAACTACAGGGATTGTAAGGG-3′	808–829

	Second round

Sense	5′GCCTTGTGTTTCTATGTTTGC-3′	277–297

Antisense	5′GCATCCATACATTCTGCGAG-3′	786–805


			(% completing step correctly) (n = 15)

		Description of step	End of traininga	7 months post trainingb	Most common error(s)

1		Work surface disinfected with alcohol	-	-	Not applicable due to change in training protocol.

2		Assembles all required equipment	87	100

3	S	Put on new pair of gloves	93	93

4		Check expiry date of RDT packet	67	80	Did not check.

5		Check desiccant sachet is dry	100	67	Did not check.

6		Write client name on cassette	80	93

7		Place cassette on level surface	100	100

8	S	Clean finger with alcohol swab	93	93

9		Allow finger to dry before pricking	100	93

10	S	Use sterile lancet to prick finger	93	93	Set down sterile lancet onto surface after removing cap

11		Puncture side of ball of the 3rd or 4th finger	100	73	Punctured vertically (i.e. perpendicular to the tip)

12	S	Dispose of lancet immediately after pricking finger	100	87	Used lancet, then set down onto work surface

13		Wipes away initial blood from finger	100	93

14	A	Uses blood collection device correctly	100	100

15	A	Correctly transfer blood to cassette using tool	100	100

16	S	Dispose of blood collection tool immediately	100	87	Left blood collection device inserted into sample well.

17	A	Dispenses correct volume of buffer	87	60	Too much buffer added.

18	A	Start the timer immediately after adding buffer	87	60	Did not record time.

19		Dispose of non-sharps safely	93	100

20a	A	States the correct time to read RDT (RDT test sheet)	100	-

20b	A	Waits correct time before reading RDT result	-	27	Waited <5 minutes before reading result.

21	A	Reads test results correctly c	80	100

22	T	Completes correct sections of treatment register	87	93

23	T	Selects appropriate AL dose based on weight	87	100	Did not record time.

24	T	Selects appropriate paracetamol dose	60	93

25	T	Selects correct Parent Information sheet for AL dose	67	40

26	T	States correct time for 2nd dose of AL to be taken	47	40	Did not complete information sheet, provided counselling verbally only


Intervention	n	Duration	% of analyzed time

Respiratory support via mask	46	8.8 (1.5-28.5) min	46.9 (15.8-97.6)b

 Sustained inflations	15	8.5 (1.8–13.8) s	2.6(0.2-8.4)c

 Mechanical ventilation	7	53.1 (6.9-128.5) s	11.6(0.5-69.8)c

Suctioning	31	34.6 (0.9-153.6) s	3.2(0.1-8.7)b

CPAP prior to nasopharyngeal tube	12	22.6 (10-39.4) minc

Stabilization prior to transport	22	27.3 (11.7-50) mind


Year	Month	BMI	Treatment	Dose	Performance status

2011		31.2

2013	Feb	29.4	FLOX C1	Oxaliplatin: 150 mg Fluorouracil: 950 mg Calciumfolinat: 110 mg	0

	March	28.7	FLOX C2	Oxaliplatin: 140 mg Fluorouracil: 900 mg Calciumfolinat: 100 mg	1

	April	27.8	FLOX C3	Oxaliplatin: 120 mg Fluorouracil: 720 mg Calciumfolinat: 100 mg	1

	June	29.2	Capecitabine	500mgx1	1-2

	July		Capecitabine/ Bevacizumab C1	500 mg × 2/ 350 mg	1-2

	Aug		Capecitabine/ Bevacizumab C2	500 mg × 2/ 350 mg	0-1

			Capecitabine/ Bevacizumab C3	500 mg × 2/ 350 mg

	Sept		Capecitabine/ Bevacizumab C4	500 mg × 2/ 350 mg

			Capecitabine/ Bevacizumab C5	500 mg × 2/ 350 mg

	Oct	29.8	Capecitabine/ Bevacizumab C6	500 mg × 2/ 350 mg	0-1

			Capecitabine/ Bevacizumab C7	500 mg × 2/ 350 mg

2014	Jan	31.2			0


Model	R2	AIC	∆AIC	Model parameters	Parameter estimate

Climate variables only – Above 1300 m

1	0.50	−217.3	0	Precipitation – 6 month lag	−0.56

Precipitation – 4 mo. Lag	0.37

2	0.48	−215.6	1.7	Precipitation – 6 mo. Lag	−1.4

Mean temperature – 0 mo. lag	0.83

Climate and crop variable – Above 1300 m

1	0.69	−232.3	0	Maize/Millet harvest – 0 mo. lag	0.47

Nut harvest – 4 mo. Lag	0.53

2	0.68	−231.0	1.3	Maize/Millet harvest – 0 mo. lag	0.51

Bean harvest – 4 + 5 mo. Lag	0.51


Constructs	mutation	XMRV p53	XMRV p58

pVP62 (WT)	None	+	+

pVP62Δgg0	_ to A (nt 372)	-	-

pVP62Δgg1	C to AT (nt 382)	-	-

pVP62Δgg2	T to C (nt 370)	+	-

pVP62Δgg3	T to C (nt 341)	-	+

pVP62Δgg4	T to G (nt 354)	-	+


Observed	Poisson	Neg. Bin	ZIP	ZINB	PLH	NBLH

1705	183	1704	1705	1705	1705	1705


HAZ or HAZ Difference	Boys	Girls

FPC1 Score b	Adj-FPC2 Scorec	FPC1 Scoreb	Adj-FPC2 Scorec

 HAZ at enrollment	−0.849	0.292	−0.971	−0.136d

 HAZ at 6 months	−0.940	0.100e	−0.982	−0.179d

 HAZ at 12 months	−0.996	−0.304	−1.000	−0.350

 HAZ at 18 months	−0.980	−0.427	−0.992	−0.459

 HAZ at 24 months	−0.979	−0.425	−0.990	−0.467

Change of HAZ %tiles from birth to age 24 months	−0.156d	−0.919	−0.047e	−0.794

Change of HAZ %tiles between age 6 and 18 months	−0.062e	−0.905	−0.028e	−0.787


	Maternal support	Paternal support

Physical activity

All children	0.37**	0.36**

Boys	0.31**	0.26*

Girls	0.45**	0.45**

Fruit and vegetable consumption

All children	0.35**	0.13

Boys	0.26*	0.25

Girls	0.46**	0.05


	Standard method	Locally-based method	Total

Period of facility assessments	March-April, 2010	July-August, 2010	March-August, 2010

Number of survey teams used	1	24	25

All unique facilities assessed	11	24	24

Sub-Health Center	2	6	6

Basic Health Centers	8	16	16

Comprehensive Health Centers	1	2	2

All patients observed/interviewed	94	216	310

All health workers interviewed	30	64	94


Category	AML with inv(16) (n = 27)	AMML without inv(16) * (n = 10)	Other types of AML * (n = 22)

Strong	20	1	7

Weak/Focal	5	3	3

Negative	2	6	12


	Number of patients (%) (N = 36)

Age

 Median (range)	58 (21–74)

≥ 65 years	10 (27.8%)

Sex

 Male	33 (91.7%)

 Female	3 (8.3%)

Hepatocellular carcinoma etiology

 Hepatitis B	26 (72.2%)

 Hepatitis C	1 (2.8%)

 Alcoholic cirrhosis	8 (22.2%)

 Other	1(2.8%)

Metastastic sites

 Lung	22 (61.1%)

 Lymph node	11 (30.6%)

 Bone	9 (25.0%)

 Other	11 (30.6%)

ECOG PS

 0	23 (63.9%)

 1	13 (36.1%)

 2	0 (0.0%)

Any prior therapy

 Sorafenib	31 (86.1%)

 Locoregional therapya	31 (86.1%)

AFP

< 200 ng/mL	22 (61.1%)

≥ 200 ng/mL	14 (38.9%)

PIVKA

< 400 mAU/mL	17 (47.2%)

≥ 400 mAU/mL	19 (52.8%)


Name	P-value	Number of molecules

Molecular and Cellular Functions

Cell Death and Survival	2.53 × 10−24 to 1.36 × 10−3	405

Cellular Growth and Proliferation	3.37 × 10−24 to 1.36 × 10−3	414

Cellular Movement	5.41 × 10−13 to 1.36 × 10−3	236

Gene Expression	8.14 × 10−11 to 1.20 × 10−3	247

Cellular Development	1.13 × 10−10 to 1.36 × 10−3	328

Physiological System Development and Function

Cardiovascular System Development and Function	4.17 × 10−12 to 1.20 × 10−3	125

Organismal Development	3.96 × 10−11 to 1.22 × 10−3	92

Tissue Development	3.68 × 10−8 to 1.22 × 10−3	163

Tumor Morphology	3.84 × 10−7 to 1.20 × 10−3	117

Connective Tissue Development and Function	8.52 × 10−6 to 1.24 × 10−3	40


Confinement	CNVR	VMR	Total

Free Roaming	1441	4812	6253

Presented by owner	20	631	651

Total	1461	5443	6904


Database	# Of Genes in Database	Last Updated 1	Database Source

ShortBRED VF 2	26,187	July 2017	https://huttenhower.sph.harvard.edu/shortbred

ShortBRED AR 3	932	July 2017	https://huttenhower.sph.harvard.edu/shortbred

Virulence Factor DataBase (VFDB)	30,246	February 2018	http://www.mgc.ac.cn/VFs/main.htm

Comprehensive Antibiotic Resistance Database (CARD)	2514	February 2018	https://card.mcmaster.ca/download


No.	Antibiotic	Abbr.	Concentration (μg)	Class

1.	Amikacin	AK	30	Aminoglycosides

2.	Amoxicillin/clavulanic acida	AMC	30	3rd generation penicillins

3.	Ampicillin	AMP	10	Aminoglycosides

4.	Aztreonam	ATM	30	Monobactams

5.	Cefamandole	MA	30	2nd generation cephalosporins

6.	Cefepime	FEP	30	4th generation cephalosporins

7.	Cefotaximea	CTX	30	3rd generation cephalosporins

8.	Cefoxitin	FOX	30	3rd generation cephalosporins

9.	Ceftazidimea	CAZ	30	3rd generation cephalosporins

10.	Cefalotin	KF	30	3rd generation cephalosporins

11.	Cefazolin	KZ	30	1st generation cephalosporins

12.	Ciprofloxacin	CIP	5	Chinolons

13.	Gentamicin	CN	10	Aminoglycosides

14.	Netilmicin	NET	30	Aminoglycosides

15.	Piperacillin	PRL	100	4th generation penicillins

16.	Piperacillin/tazobactam	TZP	110	4th generation penicillins

17.	Tetracycline	TE	30	Tetracyclines

18.	Ticarcyillin	TIC	75	4th generation penicillins

19.	Tobramycin	TOB	10	Aminoglycosides

20.	Trimethoprim/sulfamethoxazole	SXT	25	Sulfonamides


Stakeholders’ designation	Number of participants

Mobile phone programming company	1

Clinicians	4

Community health workers	4

Research team	4

District health management teams	10

Total	23


N = 3520	Total number of women	%	95% CIs

Given information during pregnancy (Told about pregnancy complications or told where to go for pregnancy complications or advised to use a skilled birth attendant)

Yes	2,872	81.6	78.5 to 84.4

Iron tablets/syrup taken

Yes	3,214	91.3	89.3 to 93.0

Given intestinal parasite drugs

Yes	2,250	63.9	60.8 to 66.9

Two or more tetanus injections given

Yes	3,033	86.2	84.2 to 87.9

Blood pressure measured

Yes	3,043	86.4	83.9 to 88.6

Blood sample taken

Yes	1,595	45.3	41.8 to 48.9

Urine sample taken

Yes	1,968	55.9	52.4 to 59.3

Received all seven ANC components

 	854	24.3	21.6 to 27.2


Early events in the disease course	EDSS outcome in patients with long term follow-up (≥ 100 months)(median, range; N)	p-level

Motor symptoms at first myelitis*Sensory symptoms at first myelitis*	7 (1.5-10; 29)5.25 (2-9; 16)	p < 0.04§

Motor symptoms at onsetSensory symptoms at onset	8.25 (5.5-10; 8)4 (2-6.5; 5)	p < 0.007§

Tetraparesis at first myelitis*Motor symptoms other than tetraparesis at first myelitis*	8.25 (7-10; 8)6 (1.5-10; 21)	p < 0.003§

> 1 myelitis attacks during the first year1 myelitis attack during the first year	8 (2.5-10; 7)5.5 (2-8.5; 11)	p < 0.035§


Toxicity	Number of Patients Reporting Toxicity by Gradea(N = 24 total toxicities)	Total

1	2	3	4	5

Pain	2	7	0	0	0	9

Fatigue	2	0	0	0	0	2

Pneumonia	0	1	1	0	0	2

Pneumothorax	0	2	0	0	0	2

Atrial Fibrillation (uncontrolled)	0	0	0	1	0	1

Dyspnea	1	0	0	0	0	1

Respiratory failure	0	0	0	1	0	1

Post-Operative Bleeding	1	0	0	0	0	1

Broncho-pleural Fistula	0	1	0	0	0	1

Generalized Weakness	1	0	0	0	0	1

Nausea	0	1	0	0	0	1

Vomiting	0	1	0	0	0	1

Anorexia	1	0	0	0	0	1


Variables (Percentage)

No. patients	74

Age (years)

 Mean	59.8 ± 15.6

 Median	62

Sex (female/male)	53/47

Mechanically ventilated	84

Oxygen by

 Mask	9

 Nasal tube	7

Central venous line	76

Intra-arterial catheter	92

Peripheral venous line	87

Vasopressor/inotropic drugs	53

APACHE II score	20 ± 8.1

Duration of transfer (min)	51.3 ± 19.1

Reason transfer

Logistic	20

Advanced therapy	80


	IQ	Working memory	Inhibitory control	Emotion recognition

Working memory	.39

Inhibitory control	.21	.11

Emotion recognition	−.16	−.11	−.09

ADHD hyperactive-impulsive	−.16	−.13	−.07	.09

ADHD inattentive	−.21	−.19	−.12	.09

Social cognition	−.14	−.11	−.05	.10

Pragmatic language	−.25	−.18	−.06	.08


Parameter	Base case (male, female)	Age 55 years	Age 60 years

Threshold	Threshold

First aseptic revision rate (early)	1.31%, 1.13%	Robust	Robust

First aseptic revision rate (late)	0.61%, 0.63%	Robust	Robust

First infection revision rate (early)	0.20%, 0.17%	Robust	Robust

First infection revision rate (late)	0.09%	Robust	Robust

End-stage osteoarthritis [1]	USD 12,815	Robust	Robust

Initial post-THA (365 days)	USD 38,965	USD 123,700 (female)USD 170,100 (male)	USD 78,800 (female)USD 116,900 (male)

Productivity	Varies by age and gender	26% of base (female)20% of base (male)	41% of base (female)28% of base (male)


Characteristics	Mean (SD)	n (%)

Gender

Male		162 (47.5)

Female		179 (52.5)

Marital Status

Single		20 (5.9)

Married		257 (75.3)

Others		64 (18.8)

Current Smoker

Yes		75 (22)

No		266 (78)

Education

Less than secondary school		243 (71.3)

Diploma		45 (13.2)

Bachelor or higher		51 (15.5)

Diabetes Treatment

Insulin		96 (28.2)

Oral tablet		165 (48.4)

Insulin + Oral tablet		78 (23.4)

Blood Sugar Self-Monitoring

Yes		300 (88)

No		41 (12)

Age (yr)	55.2 (12.9)

Body Mass Index	29.7 (5.6)

Household members	4 (2.4)

Income (USD)	630 (425)

Duration of illness (years)	11.3 (9.2)

Glycated Hemoglobin	7.9 (1.9)

No. of Cigarettes/ day	4.4 (10.1)


Filtering Criteria	Number of SNPs Excluded	Number of SNPs Remaining

None	0	2,740,205

Multiple Variants hits	33,917	2,706,288

Heterozygous and Bias*	2,111,439	594,849

Flanking Sequence**	5,482	589,367

Candidate SNPs		589,367


Congenital Malformation	Count of Exposures

	Number of dyads	Fathers (max/individual = 3)	Mothers (max/individual = 2)

		Cases	Controls	Cases	Controls

Multifactorial conditions with morphologic anomalies (excluding hip)	97	42	27	23	20

Hip dysplasia and dislocation	20	16	4	13	2


Cancer type	Mechanism	Agent	Phase

Melanoma	Anti-CTLA-4	Ipilimumab	FDA approved

Melanoma	Anti-PD-1	Nivolumab	Phase III

Melanoma	Anti-PD-1	Pembrolizumab	FDA approved

Melanoma	Adoptive cell therapy	 	Phases I-II

Melanoma	Peptide Vaccine	Melan-A peptides	Phases I-II

Melanoma	Autologous DC vaccine	 	Phases I-II

Melanoma	Whole tumor cell vaccine	 	Phases I-II

NSCLC	Peptide vaccine	EGFR peptide	Phase III

NSCLC	Anti-CTLA-4	Ipilimumab	Phase III

NSCLC	Anti-PD-1	Nivolumab	Phase II


Item	Never	Seldom (< 1/month)	Occasionally (1 to 3 times/month)	Often (1 to 2 times/week)	Frequently (≥3 times/week)

	N (%)	N (%)	N (%)	N (%)	N (%)

Applied to patient care	0 (0)	3 (14)	7 (33)	8 (38)	3 (14)

Reinforced by senior residents and faculty	0 (0)	4 (19)	12 (57)	5 (24)	0 (0)


Drug	Target	Rat study standard findings	Human clinical findings	MMtox prediction

Captopril	Kidney	Yes	Yes	Yes (∗)

Lisinopril	Kidney	Yes	Yes	Yes (∗)

Cyclosporin A	Kidney	Yes	Yes	Yes

Doxorubicin	Kidney	Yes	Yes	Yes

Phenytoin	Kidney	No	No	No

Captopril	Liver	No	Yes	Yes

Cyclosporin A	Liver	Yes	Yes	Yes

Doxorubicin	Liver	Yes	Yes	Yes

Lisinopril	Liver	No	No	No

Phenytoin	Liver	No	Yes	Yes

Cyclosporin A	Anemia	Yes	Yes	Yes

Doxorubicin	Anemia	Yes	Yes	Yes

Captopril	Bone marrow	Yes	Yes	Yes

Lisinopril	Platelet	Yes	Yes	Yes


Test Material/Chemical	Experimental Model	Findings	Reference

Xanthigen (brown marine algae fucoxanthin + pomegranate seed oil)	Mouse 3T3-L1 preadipocytes	↓ accumulation of lipid droplets in adipocytes;↓ protein levels of key adipogenesis transcription factors: PPARγ, CCAAT/enhancer binding protein (C/EBP) β, and C/EBPδ & fatty acid synthase;↑ NAD+-dependent histone deacetylases (SIRT1) and activated AMP-activated protein kinase (AMPK) signaling in differentiated 3T3-L1 adipocytes.	[63]

Brown seaweed extract (10% fucoxanthin)	Human adipose-derived stem cells	↓ ROS;Silencing of palmitic acid-induced long non-coding RNAs (lncRNAs) resulted in the decrease in lipid droplet accumulation	[57]

Fucoxanthin-rich wakame (Undaria) lipids (WL)	Mouse (Type 2 diabetes/obese model)	↓ body weight and white adipose weight;↓ plasma levels of leptin;↑ mRNA expression of β3-adrenergic receptor (Adrb3) in WAT and glucose transporter 4 (GLUT4) mRNA in skeletal muscle tissues	[45]

Fucoxanthin & Fucoxanthinol	Mouse (Type 2 diabetes/obese model)	Improved glucose tolerance;↓ TNF-γ and MCP-1 expression in WAT	[48]

Capsule containing omega-3 PUFA-rich scallop phospholipids (PL) with incorporation of Undaria lipids (UL) containing fucoxanthin	Mouse	↓ body weight and WAT weight;↑ UCP1 and mRNA expression of UCP1 in epididymal fat	[53]

Fucoxanthin (pure chemical)	Mouse	↓ IL-1β, TNF-α, iNOS, and COX-2, and suppressed maleic dialdehyde (MDA) and infiltration of polymorphonuclear cells (PMN)	[47]

Petalonia binghamiae extract containing fucoxanthin	Mouse	↓ body weight gain, adipose tissue weight and cell size, fatty droplet accumulation in the liver, and serum triacylglycerol level;↓ phosphorylation of AMP-activated protein kinase (AMPK) and acetyl-CoA carboxylase (ACC) in epididymal adipose tissue	[58]

Fucoxanthin (isolated from dried Undaria pinnatifida)	Mouse	↓ plasma triacylglycerols with a concomitant;↑ fecal lipids;↓ hepatic lipid contents;↓ activity of the hepatic lipogenic enzymes, glucose-6-phosphate dehydrogenase, malic enzyme, fatty acid synthase and phosphatidate phosphohydrolase;↑ activity of β-oxidation;↑ plasma HDL-cholesterol concentrations;↓ glucose and HbA1c	[51]

Fucoxanthin oil (1% fucoxanthin) + conjugated linolenic acid (CLA)	Rat	↓ triacylglycerol and leptin levels;↑ mRNA expression of adiponectin, adipose triacylglycerol lipase and carnitine palmitoyltransferase 1A	[50]

Xanthigen (brown marine algae fucoxanthin + pomegranate seed oil)	Human subjects	↓ body weight, waist circumference, body and liver fat content, liver enzymes (NAFLD group only), serum triacylglycerols and C-reactive protein	[62]


Variable	HR* (95% CI)	p value

Age 	1.04 (1.01–1.07)	0.014

Loss of Hemoglobin	1.23 (1.03–1.47)	0.023

Biopsy proven rejection	2.4 (1.41–4.0)	0.001


Scale	Measures

Physical Component

 Physical functioning (PF)	Limitations in physical activities due to health problems

 Role-physical (RP)	Limitations in usual daily activities due to health problems

 Bodily pain (BP)	Pain experienced due to health problems

 General health (GH)	General health perceptions

 Vitality (VT)	Self-perceived energy and fatigue

Mental Component

 Social functioning (SF)	Limitations in social activities due to physical or emotional problems

 Role-emotional (RE)	Limitations in usual daily activities due to emotional problems

 Mental health (MH)	Perceived well-being and the presence of any psychological distress


Parameters	Proposed Sensor 	XTE-190

Operational mode	Absolute	Absolute

Pressure range	2 MPa	1.7 MPa

Compensated temperature range	+20–220 °C	+25–232 °C

Sensitivity (10 V power supply)	210 mV/100 kPa	8 mV/100 kPa

Thermal zero shift Thermal sensitivity shift	±1.2%FS/100F ±1.2%/100F	±1%FS/100F ±1%/100F

Total accuracy in compensation temperature range	±2%FS	±1.5%FS


Mechanical incremental steps compression

Compression factor	Intraparticle porosity	Voidage space

(λ)	(εp)	(ε)

0.00	0.63	0.41

0.02	0.60	0.39

0.05	0.63	0.36

0.10	0.62	0.33

0.15	0.60	0.31


Group	Treatment	Sham

Men/women (number of patients)	3/17	4/16

Age (years)	43.5 ± 11.07	43.55 ± 7.82

Headache history (years)	15.25 ± 8.37	18.75 ± 9.98

Baseline VAS	7.75 ± 0.96	7.45 ± 0.88

Baseline headache duration (days/month)	21.05 ± 3.36	19.65 ± 3.66

Baseline MIDAS score	63.05 ± 19.89	63.60 ± 16.59


	Furosemide	Placebo

	PEFR	FEV1.0	PEFR	FEV 1.0

Study (year)	Baseline airflow	SD	Post-treatment airflow	SD	Baseline airflow	SD	Post-treatment airflow	SD	Baseline airflow	SD	Post-treatment airflow	SD	Baseline airflow	SD	Post-treatment airflow	SD

Alshehri and colleagues, 2005 [5]	59.0	22.0	84.9	14.0	58.5	14.5	80.2	13.9	57.2	25.4	80.7	17.4	56.7	17.3	77.8	19.1

Nuhoğlu and colleagues, 2006 [3]	178	65.9	222	66.1	N/A	N/A	183	51.7	218	60.3	N/A	N/A

	Baseline airflow	SD	Net airflow improvement above baseline	SD	Baseline airflow	SD	Net airflow improvement above baseline	SD	Baseline airflow	SD	Net airflow improvement above baseline	SD	Baseline airflow	SD	Net airflow improvement above baseline	SD

González-Sánchez and colleagues, 2002 [4]	N/A	N/A	0.820	0.460	0.910	0.067	N/A	N/A	0.850	0.340	0.980	0.078

Nannini and colleagues, 1992 [1]	147	68.0	269	89.7	N/A	N/A	234	82.0	316	56.2	N/A	N/A

Ono and colleagues, 1997 [6]	171	20.0	205	45.1	1.18	0.13		178	25.0	198	21.3	1.32	0.74	N/A

Pendino and colleagues, 1998 [2]	200	71.0	426	98.0	N/A	N/A	209	68.0	337	73.2	N/A	N/A


		Specific Production (μmol/min/mg)

Substrate	Product	Monohydroxy Fatty Acid	Dihydroxy Fatty Acid

Palmitoleic acid (16:1Δ9Z)	8-HHME	9.6 ± 0.2	NA

Oleic acid (18:1Δ9Z)	8-HOME	9.0 ± 0.1	NA

Linoleic acid (18:2Δ9Z,12Z)	8-HODE, 8,11-DiHODE	10.8 ± 0.1	1.4 ± 0.0

Conjugated linoleic acid (18:2Δ9E,12E)	NA	NA	NA

α-Linolenic acid (18:3Δ9Z,12Z,15Z)	8-HOTrE, 8,11-DiHOTrE	14.9 ± 0.0	1.1 ± 0.0

γ-Linolenic acid (18:3Δ6Z,9Z,12Z)	NA	NA	NA

Eicosadienoic acid (20:2Δ11Z,14Z)	NA	NA	NA

Dihomo-γ-linolenic acid (20:3Δ8Z,11Z,14Z)	NA	NA	NA

Arachidonic acid (20:4Δ5Z,8Z,11Z,14Z)	NA	NA	NA

Docosapentaenoic acid (22:5Δ7Z,10Z,13Z,16Z,119Z)	NA	NA	NA

Docosahexaenoic acid (22:6Δ4Z,7Z,10Z,13Z,16Z,19Z)	NA	NA	NA


Up-Regulated Genes	Down-Regulated Genes

Gene Symbol	Gene Name	Gene Symbol	Gene Name

APOLD1	Apolipoprotein L domain containing 1	AMD1	S-adenosylmethionine decarboxylase 1

Atrogin-1	F-box protein 32/Atrogin-1	AMIGO2	Adhesion molecule with Ig-like domain 2

BCL6	B-cell CLL/lymphoma 6	ATP13A3	ATPase type 13A3

BTG1	B-cell translocation gene 1	BAG2	BCL2-associated athanogene 2

C1orf183	Chromosome 1 open reading frame 183	BDNF	Brain-derived neurotrophic factor

C1orf63	Chromosome 1 open reading frame 63	BIRC3/cIAP2	Baculoviral IAP repeat-containing 3

CCNG2	Cyclin G2	CCL2	Chemokine (C-C motif) ligand 2

CLK1	CDC-like kinase 1	CCND1	Cyclin D1

CTGF	Connective tissue growth factor	CYP1B1	Cytochrome P450 subfamily I polypeptide 1

DDIT3/CHOP	DNA-damage-inducible transcript 3	DCK	Deoxycytidine kinase

EIF1/SUI1	Eukaryotic translation initiation factor 1	DIO2	Deiodinase, iodothyronine, type II

GADD45B	Growth arrest and DNA-damage-inducible β	DKFZP686E2158	Hypothetical protein LOC643155

ID1	Inhibitor of DNA binding 1	DKK1	Dickkopf homolog 1 (Xenopus laevis)

ID2B	Striated muscle contraction regulatory prot.	DSCR1	Down syndrome critical region gene 1

IRF7	Interferon regulatory factor 7	EDN1	Endothelin 1

KIF1B	Kinesin family member 1B	F3	Coagulation factor III

KLF6	Kruppel-like factor 6	FGF2	Fibroblast growth factor 2

KLHL24	Kelch-like 24	FST	Follistatin

LOC85028	PNAS-123	G0S2	Putative lymphocyte G0/G1 switch gene

MIR	Myosin regulatory light chain interacting prot.	GABPB2	GA binding protein transcription factor, β2

MT1E	Metallothionein 1E	GBP1	Guanylate binding protein 1

PCMTD1	Protein-L-isoaspartate O-methyltransferase	GBP3	Guanylate binding protein 3

PHLDA1	Pleckstrin homology-like domain family A	GLIPR1	Glioma pathogenesis-related protein

PNPLA8	Patatin-like phospholipase domain 8	GPR19	G protein-coupled receptor 19

RNU2	RNA, U2 small nuclear	GRIK1	Glutamate receptor, ionotropic, kainate 1

SAT	Spermine N1-acetyltransferase	GRO3	GRO3 oncogene

STK31	Serine/threonine kinase 31	IGFBP5	Insulin-like growth factor binding protein 5

TAF9	TAF9 RNA polymerase II	IL7R	Interleukin 7 receptor

TIEG	TGFβ inducible early growth response	ISG20L1	Interferon stimulated exonuclease

TXNIP	Thioredoxin interacting protein	LOC57090	HRPAP20 short form

ZBTB1	Zinc finger and BTB domain containing 1	LTV1	LTV1 homolog (S. cerevisiae)

	cDNA DKFZp564C2063	MAT2A	Methionine adenosyltransferase II, alpha

		MMP3	Matrix metalloproteinase 3

		NAV3	Neuron navigator 3

		NCOA7	Nuclear receptor coactivator 7

		NOLA1	Nucleolar protein family A, member 1

		NTF3	Neurotrophin 3

		NXT1	NUTF-like export factor1

		PAK1IP1	PAK1 interacting protein 1

		PLAU	Plasminogen activator, urokinase

		PPIF	Peptidylprolyl isomerase F (cyclophilin F)

		PTRH2	Peptidyl-tRNA hydrolase 2

		PTX3	Pentaxin-related gene

		RGS20	Regulator of G-protein signalling 20

		SC4MOL	Sterol-C4-methyl oxidase-like

		SFRS3	Splicing factor, arginine/serine-rich 3

		SGNE1	Secretory granule, neuroendocrine protein 1

		SNK	Serum-inducible kinase

		STC2	Stanniocalcin 2

		TNFRSF11B	Tumor necrosis factor receptor 11b (OPG)

		TRIM16	Tripartite motif-containing 16

		TSLP	Thymic stromal lymphopoietin

			cDNA FLJ11812 fis, clone HEMBA1006364


Annotation	Figure 1A*	S. pneumoniae TIGR4	S. pneumoniae G54	S. mitis B6	S. oralis Uo5	S. gordonii V288	S. sanguinis SK36

Regulator	1	SP1674	SPG1583	smi0612	SOR0560	SGO0127	SSA0081

Hypothetical protein	2	-	-	smi0610	SOR0559	SGO0126	SSA0080

N-acetylmannosamine kinase	3	SP1675	SPG1584	smi0609	SOR0558	SGO0125	SSA0079

N-acetylneuraminate lyase	4	SP1676	SPG1585	smi0608	SOR0557	SGO0124	SSA0078

hypothetical protein	5	SP1677	SPG1586	smi0607	SOR0556	-	-

hypothetical protein	6	SP1679	-	-	-	-	-

hypothetical protein	7	SP1680	SPG1588	smi0606	SOR0555	-	-

satA ABC transporter permease	8	SP1681	SPG1589	smi0605	SOR0553	-	-

satB ABC transporter permease	9	SP1682	SPG1590	smi0604	SOR0552	-	-

satC ABC transporter substrate-binding protein	10	SP1683	SPG1591	smi0603	SOR0550	-	-

PTS system, IIBC components	11	SP1684	SPG1592	-	-	-	-

NanE, ManAc-6P 2-epimerase	12	SP1685	SPG1593	smi0602	SOR0549	SGO0118	SSA0071

oxidoreductase	13	SP1686	SPG1594	-	-	SGO0123	SSA0077

NanB neuraminidase	14	SP1687	SPG1595	-	-	-	-

ABC transporter permease	15	SP1688	SPG1596	-	-	SGO0122	SSA0076

ABC transporter permease	16	SP1689	SPG1597	-	-	SGO0121	SSA0075

ABC transporter substrate-binding protein	17	SP1690	SPG1598	-	-	SGO0120	SSA0074

hypothetical protein	18	SP1691	SPG1599	-	-	SGO0119	SSA0073

NanA neuraminidase	19	SP1693	SPG1600	smi0601	SOR0548	-	-

Acetyl xylan esterase	20	SP1694	SPG1601	smi0600	SOR0547	-	SSA0070


Cell line class	S:MI	S:MER	MER:MI	Significant predictive relationships

HMEC	<0.0001**	0.006**	0.0120*	S→MER, MER→MI, and S→MI

BL	0.5996	0.5954	0.1659	N/A

LumB	0.0041*	0.4769	<0.0001**	MER→MI, S→MI

CL	0.4827	0.3758	0.0051*	MER→MI

Her2E	0.0706	0.3090	0.1309	N/A


	cluster α	hybrid	cluster β

Lineage 1	80	0	1

Lineage 2	22	7	82


PCMP Samples	Sample 1#	Sample 2#	Sample 3#	Sample 4#	Sample 5#	Sample 6#	Sample 7#	Sample 8#	Sample 9#

AP percentage (%)	0	2.5	5	7.5	10	12.5	15	17.5	20

Heat transfer coefficient (W/m2·K)	2.38	2.42	2.59	2.68	2.84	2.98	3.05	3.11	3.24


Guliver coding System	Total sample	NL	IT	UK	BE

Category

Non-verbal behaviour	69.1	74.4	90.0	59.0	62.6

Structuring	86.0	94.1	92.3	68.5	89.8

Summarizing	84.2	97.8	78.0	71.4	87.1

Patient involvement	71.7	97.3	76.7	71.1	72.3

Speaking peculiarities	27.7	23.1	41.7	17.9	36.8

Task-oriented attitude	95.6	95.9	99.6	92.2	95.3

Collecting information	74.8	81.7	89.4	63.5	69.5

Giving information	91.4	86.7	100	87.9	92.8

Providing solution	95.3	100	97.2	73.3	97.0

Affective-oriented attitude	97.2	95.3	100	95.1	97.9

Total	86.6	86.7	93.8	78.6	87.8


Variable	Placebo (n = 25)	Telotristat ethyl

250 mg tid (n = 25)	500 mg tid (n = 25)

Mean (s.d.)	Mean (s.d.)	P	95% CL	Mean (s.d.)	P	95% CL

BM frequency

 Change from baseline in BM frequency averaged over 12 weeks, counts/day	0.05 (0.33)	−0.45 (0.69)	−	−	−0.60 (0.72)	−	−

 Arithmetic mean treatment difference	−	−0.50	−	−0.81 to −0.19	−0.65	−	−0.96 to −0.33

 Hodges–Lehmann estimator	−	−0.45	0.004	−0.72 to −0.17	−0.54	<0.001	−0.79 to −0.25

Stool consistency

 Change from baseline in stool consistency averaged over 12 weeks (Bristol Stool Form scale)	0.01 (0.41)	−0.20 (0.70)	–	–	−0.60 (0.86)	–	–

 Arithmetic mean treatment difference	−	−0.20	–	−0.53 to 0.13	−0.60	–	−0.99 to −0.22

 Hodges–Lehmann estimator	−	−0.20	0.09	−0.45 to 0.02	−0.39	0.009	−0.82 to −0.12

Flushing

 Change from baseline in daily cutaneous flushing episodes averaged over 12 weeks, counts/day	−0.33 (1.22)	−0.06 (0.98)	–	–	0.11 (2.10)	–	–

 Arithmetic mean treatment difference	−	0.27	–	−0.36 to 0.90	0.45	–	−0.53 to 1.42

 Hodges–Lehmann estimator	−	0.11	0.67	−0.17 to 0.61	0.02	0.58	−0.28 to 0.62

Abdominal pain

 Change from baseline in abdominal pain averaged over 12 weeks, 11-point numeric rating scale	−0.06 (0.78)	−0.23 (0.97) 	–	–	0.03 (0.77)	–	–

 Arithmetic mean treatment difference	−	−0.17	–	−0.67 to 0.33	0.09	–	−0.35 to 0.53

 Hodges–Lehmann estimator	−	0.06	0.61	−0.42 to 0.33	0.14	0.66	−0.39 to 0.51

Rescue short-acting SSA use

 Change from baseline in rescue short-acting SSA use averaged over 12 weeks, counts/day	−0.01 (0.14)	−0.07 (0.35)	–	–	0.01 (0.10)	–	–

 Arithmetic mean treatment difference	−	−0.05	–	−0.20 to 0.10	0.02	–	−0.05 to 0.09

 Hodges–Lehmann estimator	−	0.00	0.45	0.00–0.00	0.000	0.98	0.00–0.00


Gene Title and Abbreviation (The GENE Database)	Percent Change

OPRM1, 1 opioid receptor, mu 1	+1294

TP73, 2 tumor protein p73	+938

KCND1, 3 potassium voltage-gated channel, Shal-related subfamily, member 1	+845

SLC8A2, 4 solute carrier family 8 (sodium/calcium exchanger), member 2	+737

CNTNAP2, 5 contactin associated protein-like 2	+581

STMN3, 6 stathmin-like 3	+500

LPHN3, 7 latrophilin 3 	+494

ANGPT1, 8 angiopoietin 1	+487

SYN3, 9 synapsin III	+478

DPP6,10 dipeptidyl-peptidase 6	+448

PITX3, 221 paired-like homeodomain 3	−541

NOTCH3, 222 notch 3	−547

DLGAP1, 223 discs, large homolog-associated protein 1	−547

SLIT1, 224 slit homolog 1	−553

BSN, 225 bassoon (presynaptic cytomatrix protein)	−563

CELSR1, 226 cadherin, EGF LAG seven-pass G-type receptor 1	−647

CACNB4, 227 calcium channel, voltage-dependent, beta 4 subunit	−672

NDN, 228 necdin homolog (mouse)	−729

EDNRB, 229 endothelin receptor type B	−768

CHRM2, 230 cholinergic receptor, muscarinic 2	−1049


 	Predicted change in hazard for one unit change in variable	Significance (P)

HADS anxiety	1.012 (0.39–2.58)	0.98

HADS depression	0.82 (0.22–3.05)	0.76

PANAS negative affect	1.07 (0.33–3.47)	0.90

Mood rating scale	1.20 (0.48–3.0)	0.68

FACT C FW	0.56 (0.16–1.89)	0.81

FACT C AC	0.37 (0.16–0.89)	0.02

TNM	4.35 (1.93–9.8)	<0.001


Author, Year [Reference]	Study Design	StudyPopulationParticipantsAgeBMIHealth Status	Intervention and Doses	Duration Weeks	Observed Effects

Pol, 2013 [28]	Meta-analysis of 26 RCTs	2060 M/F18–70 years18.5–35.8 kg/m2Healthy	Whole grain (mean dose: 84.1 g/day)vs. refined grain	2–16	= BW↓ body fat: −0.48%vs.refined grain

Kim, 2016 [29]	Meta-analysis of 21 RCTs	940 M/F47–57 years27.6–31.4 kg/m2Metabolic syndrome	Dietary pulses (mean dose: 142 g/day)vs. control	4–12	↓ BW: −0.34 kgvs.control

Mytton, 2014 [30]	Meta-analysis of 8 RCTs	1026 M/F30–75 years23.7–37.8 kg/m2Healthy	High fruit and vegetablesvs. low fruit and vegetables consumption(mean dose difference in vegetables and fruit consumptionbetween arms 133 g/day)	4–52	↓ BW: −0.54 kgvs.low fruit and vegetables

Thompson, 2017 [31]	Meta-analysis of 12 RCTs	609 M/F20–70 years25–35 kg/m2Healthy	Soluble fibre supplementation (mean dose: 18.5 g/day)vs. control	2–17	↓ BMI: −0.84 kg↓ BW: −2.52 kg↓ body fat: −0.41%vs.control


Repeat type	Structured	Unstructured

	RONN	DISOPRED	IUPRED	RONN	DISOPRED	IUPRED

E	3	13	10	97	87	90

P	6	5	5	94	95	95

A	32	23	63	68	77	37

S	4	6	16	96	94	84

L	100	97	100	0	3	0

G	11	8	14	89	92	86

Q	13	3	14	87	97	86


mRNA	Primersa

MMP-13	Fw: 5'-TTGGTCAGATGTGACACCTCRv: 5'-ATCGGGAAGCATAAAGTGGC

Cathepsin K	Fw: 5'-AGGTGGATGAAATCTCTCGGRv: 5'-TTCTTGAGTTGGCCCTCCAG

5-LOX	Fw: 5'-TGCGTTCCAGTGACTTCCACRv: 5'-CTCTGCACCATCTGCACGTG

ADAMTS-4	Fw: 5'-TACTACTATGTGCTGGAGCCRv: 5'-AGTGACCACATTGTTGTATCC

ADAMTS-5	Fw: 5'-GGCATCATTCATGTGACACRv: 5'-GCATCGTAGGTCTGTCCTG

GAPDH	Fw: 5'-AGGCTGTGGGCAAGGTCATCRv: 5'-AAGGTGGAAGAGTGGGTGTC


Population	GO ID	Gene ontology term	Genes under GO term	Related environmental stressor(s)	Reference

Kuroilers	GO:0060584	Regulation of prostaglandin-endoperoxide synthase activity	EDN2, EDN1	Oxidative stress/Pathogen	Lee et al. 2007 [89]

	GO:0007631	Feeding behavior	HCRTR2, HTR1B, GRIN1, NPY1R, ASIP	Nutrient stress	UniProt [67], Jenuth 2000 [69, 77]

	GO:0032693	Negative regulation of interleukin-10 production	TRIB2, IL-12B	Pathogen	UniProt [67], Jenuth 2000 [69, 77]

	GO:0051341	Regulation of oxidoreductase activity	ACVR2A, EDN2, EDN1, SNCA	Oxidative stress/Pathogen	UniProt [67], Jenuth 2000 [69, 77], Lee et al. 2007 [89]

	GO:0007618	Mating	ACVR2A, SERPINE2, GRIN1	Survival Behavior	UniProt [67], Jenuth 2000 [69, 77]

	GO:0016627	Oxidoreductase activity, acting on the CH-CH group of donors	IVD, CPOX, ACAD9, DHCR24	Oxidative/Environmental Stress	UniProt [67], Jenuth 2000 [69, 77], Lee et al. 2007 [89]

	GO:0006950	Response to stress	ENTPD1, ETFDH, WNT5A CHID1, RBBP5, NEDD4, NSMCE2, GLP1R, STX2, LEAP2, RAB23, DEAF1, TNFSF11, PPP2R5C, DRD4, ZC3HAV1, CDH8, PPAP2B, GTF2H5, MCPH1, EDN1, FAM175B, GCLM, JAK1, UBXN2A, MID1, BATF, CPEB2, IL12B, PIK3AP1, SOX2, SNCA, CITED2, CHAC1, DTL, HIPK3, NOS1, STT3B, PDIA4, SBNO2, NUAK1, CDC7, SERPINE2, ULK1, MASP2, WFS1, DHCR24, PRKD1	Oxidative/Metabolic/Environmental Stress	UniProt [67], Puvadolpirod et al. 2000 [48], Li et al. 2011 [70], Yen et al. 2014 [90]

	GO:0080134	Regulation of response to stress	WNT5A, CHID1, PIK3AP1, IL12B, STX2, SNCA, HIPK3, TNFSF11, ZC3HAV1, PPAP2B, SBNO2, NUAK1, MCPH1, EDN1, SERPINE2, ULK1, WFS1, MID1	Oxidative/Metabolic/Environmental Stress	UniProt [67], Puvadolpirod et al. 2000 [48], Li et al., 2011, Yen et al., 2014

	GO:0033554	Cellular response to stress	WNT5A, RBBP5, BATF, CPEB2, NEDD4, NSMCE2, SNCA, CHAC1, CITED2, DTL, HIPK3, RAB23, TNFSF11, PPP2R5C, PDIA4, GTF2H5, NUAK1, FAM175B, EDN1, CDC7, ULK1, WFS1, UBXN2A, MID1, PRKD1	Oxidative/Metabolic/Environmental Stress	UniProt [67], Puvadolpirod et al. 2000 [48]

	GO:0045859	Regulation of protein kinase activity	TNFSF11, DRD4, WNT5A, TGFBR2, RAPGEF2, PDGF, PIK3CA, KIAA1199, LATS2, IL12B, EDN1, PAQR3, SNCA, GTPBP4, HIPK3	Oxidative/Metabolic/Environmental Stress	UniProt [67], Jenuth 2000 [69, 77]

	GO:0003100	Regulation of systemic arterial blood pressure by endothelin	EDN2, EDN1	Oxidative/Metabolic Stress	Endemann et al. 2004 [20], Gomez et al. 2007 [21]

	GO:0048010	Vascular endothelial growth factor receptor signaling pathway	FIGF, NEDD4, GRB10, PRKD1	Oxidative/Metabolic Stress	Koch et al., 2012 [57]

	GO:0004674	Protein serine/threonine kinase activity	CDC42BPB, DCLK1, TGFBR3, TGFBR2, PRKCA, LATS2, ACVR2A, NUAK1, CDC7, ULK1, CDC2L1, HIPK3, VRK1, PRKD1	Oxidative/Metabolic/Environmental Stress	UniProt [67], Evans et al. 2002 [46], Perkins et al. 2007 [55], Salminen et al. 2008 [87], Tam et al., 2012 [88]

	GO:0009628	Response to abiotic stimulus	GPR65, GRIN1, CASP8, IL12B, CPEB2, SOX2, NEDD4, TNFRSF8, CITED2, DTL, ER81, NOS1, DEAF1, CNGA2, CDH8, MME, GTF2H5, HR1B, SERPINE2, EDN1, FAM175B	Oxidative/Metabolic/Environmental Stress	Mashaly et al. 2004 [92], Mujahid et al. 2005 [16]

	GO:0004672	Protein kinase activity	CDC42BPB, DCLK1, PRKCA, HIPK3, VRK1, ROR1, TRIB2, TGFBR3, TGFBR2, LATS2, ACVR2A, NUAK1, CDC7, ULK1, CDC2L1, PEAK1, JAK1, RPS6KC1, PRKD1	Oxidative/Metabolic/Environmental Stress	UniProt [67], Jenuth 2000 [69, 77]


Source	F ratio	p

Method	7.377	0.013

Method × group	0.373	0.547

Task	35.697	0.000

Task × group	0.030	0.865

Hemisphere	0.310	0.583

Hemisphere × group	0.692	0.414

Method × task	4.838	0.039

Method × task × group	0.005	0.945

Method × hemisphere	0.047	0.831

Method × hemisphere × group	0.042	0.839

Task × hemisphere	0.035	0.853

Task × hemisphere × group	0.207	0.653

Method × task × hemisphere	0.009	0.924

Method × task × hemisphere × group	0.123	0.730


Solvents	SC16-Lu	TC18-Lu	TC16-Lu	TC14-Lu	TC12-Lu

Acetone	I	I	G (1.5)	I	PS

Aniline	S	G (2.0)	G (2.0)	G (1.5)	PS

Toluene	PS	PS	I	PS	PS

Pyridine	S	S	G (2.0)	S	S

Isopropanol	PS	G (2.5)	G (2.0)	PS	PS

Cyclopentanone	PS	G (2.0)	G (1.5)	PS	PS

Cyclohexanone	PS	PS	G (2.0)	PS	PS

Nitrobenzene	S	G (2.0)	G (2.0)	G (2.0)	PS

n-Butanol	PS	G (2.5)	G (2.0)	PS	PS

Ethanolamine	G (2.0)	PS	I	S	PS

n-Butyl acrylate	PS	PS	S	PS	PS

1,4-Dioxane	PS	G (2.5)	G (2.0)	S	PS

Petroleum ether	S	G (2.0)	S	S	PS

Ethyl acetate	PS	PS	S	PS	PS

Dichloromethane	PS	S	S	S	S

THF	I	PS	S	PS	PS

DMF	PS	G (2.0)	G (1.5)	G (1.5)	S

DMSO	G (2.5)	PS	I	G (2.0)	PS

Ethanol	PS	G (2.0)	G (2.0)	PS	PS

Benzene	PS	PS	I	S	PS

Tetrachloromethane	PS	PS	PS	S	S

Acetonitrile	PS	PS	PS	PS	PS

Methanol	PS	PS	S	PS	PS

n-Pentanol	PS	G (2.5)	G (2.0)	PS	PS

Cyclopentanol	PS	G (2.0)	S	PS	PS

Formaldehyde (aq.)	PS	PS	PS	PS	PS


 	Biocatalyst	S/B	RS%	Xyl%	Glc%	Useful results

1	TL-xylanase	3.3	23.5	2.26	8.6	xylobiose 3.3 g/L

pentasaccharide 1 (Figure 2), 2 g/L

2	TM-xylanase	2.6	38	0	0	-

3	CFE-TT	3.5	90	19.2	16.9	-

4	CFE-TT	1.2	100	28.6	6.8	-

5	CFE-TT	3.5	20	8.7	7.8	tetrasaccharide 2 (Figure 2) 2.64 g/L

6	CFE-TN	1.2	75	40.5	15.2	see Figure 3

7	ES-GTM1b	13.5	73.5	26.5	0	see Figure 3

8	ES-GTM1a	36.3	63.1	9.85	0	see Figure 3

 	 	 	Comment

9	TM-xylanase	7.7	Formation of mono and dixylosylated acceptor

10	CFE-TN	1.2	Formation of mono and dixylosylated acceptor

11	ES-GTM1	13.5	Formation of mono, di and trixylosylated acceptor

12	CFE-TT	3.5	Formation of mono and dixylosylated acceptor


	Reason for hysterectomy		Number of women with vaginal bleeding	Odds ratio (95% CI)

Supracervical abdominal hysterectomy	Fibroids	Yes	16	0.66 (0.16, 2.71)*

No	3

Heavy bleeding	Yes	11	1.28 (0.49, 3.35)*

No	8

Pain and/or endometriosis	Yes	5	1.37 (0.43, 4.32)*

No	14

Supracervical laparoscopic hysterectomy	Fibroids	Yes	33	0.47 (0.23, 0.93)*

No	24

Heavy bleeding	Yes	41	 4.07 (1.32, 12.57)*

No	16

Pain and/or endometriosis	Yes	23	0.41 (0.20, 0.85)*

No	34


Comparator	Correlation [95% CI] with UCEIS	Correlation [95% CI] with Modified Baron Scorea

Full MCS+ [including endoscopy]	0.86 [0.83, 0.88]	N/Ab

Partial MCS [excluding endoscopy]	0.82 [0.79, 0.85]	0.77 [0.61, 0.88]

Stool frequency subscore	0.76 [0.72, 0.80]	0.73 [0.53, 0.85]

Rectal bleeding subscore	0.82 [0.78, 0.85]	0.74 [0.54, 0.85]

Both stool frequency and rectal bleeding	0.81 [0.77, 0.84]	0.77 [0.58, 0.87]

Patient functional assessment subscore	0.76 [0.71, 0.79]	0.52 [0.24, 0.72]

Modified Baron scorea	0.78 [0.74, 0.81]	-


	Vials with FA detectedn (%)	Vials without FAn (%)

Infundibulae or surface structures on sections	376 (72.6)	94 (18.1)

No infundibulae or surface structures on sections	0 (0.0)	48 (9.3)


Variable	Number	%

Age, mean ± SD	69.0 ± 10.2

Sex

 Male	159	70.7

 Female	66	29.3

Histology

 Adenocarcinoma	139	61.5

 Squamous cell	67	30.1

 NSCLC-NOS	10	4.4

 Pleomorphic	5	2.2

 Adenosquamous	4	1.8

Pathological stage

 IA	78	34.5

 IB	53	23.9

 IIA	23	10.2

 IIB	24	10.6

 IIIA	36	15.9

 IIIB/IV	11	4.9


Microorganisms	Isolation Sites	Applications	Enzyme	Reference

Pseudoalteromonas haloplanktis	Antarctica	Starch conversion; detergent	Amylase Endo-amylase	[106]

Zunongwangia profunda	Deep-sea, China	Starch conversion; detergent	Alpha-amylase	[107]

Martelella mediterranea	Lake Martel, Spain	cellulose conversion; detergent	Beta-glucosidase	[22]

Desulfotalea psychrophila	Marine sediments, Antarctica	Agriculture; food; pharmaceutical industries	Esterase	[108]

Pseudoalteromonas haloplanktis	Marine Antarctic	Detergent	Lipase	[98]

Psychrobacter sp. wp37	Deep-sea sediments, West Pacific	Detergent	Lipase	[109]

Microorganisms	EPS-Structure and Chemical Composition 1	Applications and Activity	Reference

Pseudomonas sp. ID1	Carbohydrates 33.8% (Glc 17.0%, Gal 8.6%, Fuc 8.2%)/Uronic acids 2.4%/Proteins 2.8%	Cryo-protection and emulsifying activities	[110]

Pseudomonas strain CAM025	Glc/GalA/Rha/Gal Molar ratios: 1:0.5:0.1:0.08	Cryo-protection and trace metal binding	[110]


Indicator

A Ratio of native Dutch within total population: both parents were born in the Netherlands

B Ratio of Moroccan origin within total population: person or at least one parent was born in Morocco

C Ratio of Turkish origin within total population: person or at least one parent was born in Turkey

D Ratio of Surinamese origin within total population: person or at least one parent was born in Surinam

E Ratio of Antillean origin within total population: person or at least one parent was born in the Netherlands Antilles


Characteristics	Total population

n = 3807

Gender

Male	42.1 %

Age (years)

Mean (SD)	78 (7.68)

Range	65–102

Number of chronically used drugs

Median (IQR)	9 (7–11)

Mean (SD)	9.54 (3.40)

Range	5–27

Number of DRPs

Median (IQR)	2 (1–4)

Mean (SD)	3.00 (2.26)

Range	1–26


	Total group (n = 270)	Subgroup (n = 141)

Haemoglobin (g/dl)	13.1 ± 0.9	13.2 ± 0.9

Haematocrit (%)	39.2 ± 2.7	39.2 ± 2.8

Mean Corpuscular Volume (fl.)	87.2 ± 5.0	86.9 ± 5.0

Serum Ferritin (ng/ml)	25.1 ± 21.3	25.5 ± 16.9

Serum Transferrin (mg/dl)	307.5 ± 54.1	311.5 ± 56.7

Serum iron (μg/dl)	81.7 ± 37.5	80.0 ± 36.

Transferrin saturation (%)	19.4 ± 10.2	18.8 ± 8.7


Layers	Attacks

Physical layer	Jamming, Node tampering

Link layer/medium access control	Collision, exhaustion, and unfairness

Network and routing layer	Neglect and greed, homing, misdirection, spoofing, replaying, routing-control traffic or clustering messages

Transport layer	Flooding and De-synchronization

Application layer	Overwhelming sensors, reprogramming attack


	ADC: SUVmax	SQC: SUVmax

Factor	Low	High	Pvalue	Low	High	Pvalue

Pleural invasion			0.027			0.064

 No	19	19		17	9

 Yes	2	12		1	5

Vascular invasion			0.042			0.735

 No	17	16		9	6

 Yes	4	15		9	8

Nodal status			0.016			0.365

 N0	21	23		16	10

 N1 + 2	0	8		2	4

Cox-2 expression			0.001			0.473

 Negative	13	5		12	7

 Positive	8	26		6	7

Ki-67 expression			0.011			0.087

 Negative	15	11		11	4

 Positive	6	20		7	10

VEGF expression			0.003			0.999

 Negative	12	5		9	7

 Positive	9	26		9	7


Accession	Hydroxycinnamic Acids	ORAC	DPPH	TRC	NO Inhibition

S. muricatum

37-A	5	2	4	2	1

El Camino	3	4	5	4	5

Puzol	2	3	2	5	2

Valencia	1	5	3	3	4

S. caripense

E-7	4	1	1	1	3


Region	Diseased animals	Apparently healthy animals	Total

Number of isolates as detected from 16SrRNA	Positive for SeM gene	Number of isolates as detected from 16SrRNA	Positive for SeM gene	Number of isolates as detected from 16SrRNA	Positive for SeM gene

R.S. Pura	4	0	1	0	5	0

Katra	12	2	3	0	15	2

Total	16	2	4	0	20	2


	Brain region	Hemisphere	NVtxs	Size (mm2)	X	Y	Z	Max	CWP

Group comparisons

HC > CD	Superior temporal gyrus	R	338	154.4	64	−37	13	3.5	0.001

CD > HC	None significant at CWP ≤ 0.001

CO-CD > AO-CD and vice-versa	None at CWP ≤ 0.001

Correlation with CU traits in the CD group

Negative correlation	Lingual gyrus	L	399	168.9	−22	−54	−2	4.3	0.0007

Positive correlation	None at CWP ≤ 0.001

Correlation with lifetime CD symptoms in the CD group

Negative correlation	Inferior parietal lobule	R	344	184.6	45	−64	32	3.5	0.0002

Positive correlation	Inferior frontal gyrus (pars opercularis)	R	297	169.5	47	25	20	3.2	0.0007


NHI Code	Treatment	(n = 13,261)	%

45010C	Supportive individual psychotherapy	2117	16.0

45087C	Re-educative individual psychotherapy-adult	1578	11.9

45088C	Re-educative individual psychotherapy: 6–15 years old	127	1.0

45100C	Behavior modification assessment	49	0.4

45013C	Intensive individual psychotherapy-adult	34	0.3

45016C	Supportive group psychotherapy	33	0.2

45094C	Re-educative group psychotherapy	24	0.2

45022C	Activity therapy (day)	24	0.2

45043C	Biofeedback therapy	14	0.1

45089C	Re-educative individual psychotherapy-under 6 years old	12	0.1

45095C	Special Occupational therapy	10	0.1

45090C	Intensive individual psychotherapy: 6–15 years old	7	0.1


	All patients	L5/S1 herniations with high iliac crest	Herniations with scoliosis	Herniation with calcification

No. of patients in category	209	29	25	31

Excellent or good n (%)	200 (95.7)	29 (100)	25 (100)	30 (96.8)

Fair n (%)	6 (2.9)	0 (0)	0 (0)	1 (3.2)

Poor n (%)	3 (1.4)	0 (0)	0 (0)	0 (0)


Study reference	Study design	Reported inclusion/exclusion criteria	Reported double blind	Reported clinically-labeled products	Reported sample power estimation	Reported adverse events	Reported study completion ratio	Overall quality factor scores

Study 2 from Lloyd et al. 1999 [8]	Randomized Parallel group	1	1	1	1	0	1	5/6

Study 1 from Lloyd et al. 1999 [8]	Randomized Parallel group	1	1	1	0	0	1	4/6

Study 1 from Ostrom et al. 2002 [7]	Randomized Crossover	0	1	1	0	0	1	3/6

Study 2 from Ostrom et al. 2002 [7]	Randomized Crossover	1	1	1	0	0	1	4/6

Borschel et al. 2012 [11]	Randomized Parallel group	1	1	1	1	1	1	6/6

Borschel et al. 2014 [10]	Randomized Parallel group	1	1	1	1	1	1	6/6

Leite et al. 2013 [9]	Randomized Crossover 1	1	1	0	1	1	1	5/6

Nelson et al. 1996 [6]	Randomized Crossover	0	0	1	0	1	1	3/6

Nelson et al. 1998 [5]	Randomized Crossover	0	1	1	0	1	1	4/6


 	WT	+/-	-/-

Early-stage seizure	0	+	++

Myoclonic jerks	0	+*	0

Clonic seizure	0	−*	−−

Repetitive jumping	0	(+)	++

Social preference	0	(+)	++

Ultrasonic vocalization	0	(−)*	−−

Nest building	0	−	−−

Acoustic startle response	0	−	−−

Prepulse inhibition	0	(−)	−−

Cue test (fear conditioning)	0	(−)	−−


Targeted agent	Chemotherapy	N	RR	PFS (months)	OS (months)	Reference

Cetuximab	Irinotecan and FU	49	42%	8.6	16.6	Kanzler et al. [11]

Bevacizumab	Docetaxel, FU and cisplatin	44	67%	12	16.2	Kelsen et al. [12]

Cetuximab	Irinotecan and oxaliplatin	51	60%	6	9.5	Woell et al. [13]


ID	Protein change	aNucleotide change	Mutation type	dPolyPhen-2	eSIFT	Predicted function	Mutant ratio

777T	Y249X	747T>A		nonsense		Loss of function	0.91

869T	G869E	2606G>A	missense	damaging	damaging	Damaging	0.51

163T	C911F	2732G>T	missense	damaging	tolerated	Uncertain	0.49

324T	S947C	2840C>G	missense	benign	damaging	Uncertain	0.61

970T	P226RfsX4	677_693del17	frameshift			Loss of function	0.19

981T	P226RfsX4	677_693del17	frameshift			Loss of function	0.23

1278T	F1250del	3747_3749del	in-frame del			Uncertain	0.14

bACCMESO1	V132EfsX3	395_399del5	frameshift			Loss of function

cNYU695	K674SfsX73	2020delA	frameshift			Loss of function


No.	Age	Gender	BSA (m2)	MSKCC risk	Metastatic sites	Prior therapy

1	70	Female	1.298	Intermediate	Lung, Lymph nodes	None

2	58	Female	1.446	Favorable	Abdominal wall, Lung, liver	None

3	56	Male	1.929	Intermediate	Lung	Interferon

4	79	Male	1.710	Favorable	Pancreas, Contralateral kidney	None

5	62	Male	1.893	Favorable	Pleura	None

6	64	Male	1.659	Intermediate	Lung	None


Sequence	Faster adaptation for the lens of period 1 (immediate or few hours)	No difference	Faster adaptation for the lens of period 2 (immediate or few hours)	TOTAL

	N	N	N	N

New-generation lens then older-generation lens	14	35	12	61

Older-generation lens then new-generation lens	5	39	19	63

TOTAL	19	74	31	124


Outcomes	Lifestyle intervention group n = 27a	Close follow-up group n = 27	p valueb

Total weight gain (kg)	11.4 ± 6.0	13.9 ± 5.1	NS

Weight at the end of pregnancy ( kg)	88.6 ± 14.4	84.1 ± 11.3	NS

Fasting glucose (mmol/l)	4.6 ± 0.4	4.4 ± 0.3	NS

OGTT 1-hour glucose (mmol/l)	6.9 ± 1.7	6.9 ± 1.7	NS

OGTT 2-hour glucose (mmol/l)	6.1 ± 1.4	6.0 ± 1.2	NS

Area under the curve (mmol/l/2 h)	12.3 ± 2.4	12.1 ± 2.2	NS

Gestational diabetes	3 (11.1)	1 (3.7)	NS

Insulin therapy	0	0	NS


Working countries	Health problems suffered during last 12 month	Total

	Yes (%)	No (%)

Qatar	120 (58.5)	85 (41.5)	205

Saudi Arabia	74 (54.0)	63 (46.0)	137

United Arab Emirates	37 (56.1)	29 (43.9)	66

Total	231 (56.6)	177 (43.4)	408

Working countries	Accident at the work place	Total

	Yes (%)	No (%)

Qatar	47 (22.9)	158 (77.1)	205

Saudi Arabia	36 (26.3)	101 (73.7)	137

United Arab Emirates	19 (28.8)	47 (71.2)	66

Total	102 (25.0)	306 (75.0)	408


Studies	n	Procedures	Mean age ± SD (yr) (min–max)	Described complication	% found in each study	Equivalent % in our cohort

Sury et al., 1999 [3]	1155	MRI	N/A	Failure	5	2.3

Beebe et al., 2000 [9]	572	MRI	5 ± 4(2 mo–14 yo)	Inadequate sedation	7.9	7.3

				Total	20.1	22

Malviya et al., 1997 [1]	1140	MRI (48%) CT (27%) Cardiac (22%)	3 ± 3.7	Inadequate sedationFailureDesaturation ≤90%	13.23.785.5	82.35.77

				Total	6.52	22

Lightdale et al., 2009 [11]	5045	Imaging (81%)	3.3 (1.4–6.4)	Serious adverse events*FailureDesaturation§	1.921.170.57	02.30

Haque and Fadoo, 2010 [12]	499	Oncology	4.2 (6 mo–14 yo)	Desaturation¥Apnea	2.40.6	5.770

Cravero et al., 2006 [13]	30037	Imaging (60%) Oncology (9%) GI (6%)	0–6 mo : 6% 6 mo–2 yo : 23% 2–8 yo : 47% 8 yo+ : 29%	Desaturation ≤90%Apnea	1.570.24	5.770

Cravero et al., 2009 [10]	49836	Imaging (60%) Oncology (14%) GI (11%)	0–6 mo : 2% 6–12 mo : 6% 1-2 yo : 12% 2–4 yo : 21% 4–8 yo : 28%8 yo+ : 29%	Desaturation ≤90% for 30 sApnea	1.545.75	5.770

Lavoie, 2012	448	Imaging (41%) GI (10%)	4.1 ± 4.3 (1 mo–18 yo)	FailureDesaturation ≤90%ApneaMajor complication	2.35.7700	————


Method	Temporal resolution	Measure	Span of interest	General functionality	Hypothesized emotion-related functionality

ERP	Higher (as low as 1 ms)	Amplitude fluctuations evoked by stimulus	Short (∼1 s)	Early (e.g., P1, N1, N170)	Perceptual feature extraction	Early selective attention to affective stimuli

				Middle (e.g., P2, N2)	Executive control, selective attention	Retrieving concept knowledge for evaluation of affective state

				Late (e.g., P3, N4, Late Positive Potential)	Semantic processing, memory, evaluation	Using concept knowledge for evaluation of affective state

ERD/ERS	Lower [few multiple of ERPs (Knösche and Bastiaansen, 2002)]	Decrease or increase of induced power in given frequency band	Long (1 s∼)	Activation or suppression of cortical activity. Alpha band oscillation is related to the access to concept knowledge. Gamma band is associated with processing of affective stimuli.


Clinical Features	MBD5-specific mutation20,22–24	2q23.1 Deletion20,22–24	Case in this study

 	Number	Percentage	Number	Percentage	+, present; - absent

Neurological

 Development delay	20/21	95%	53/55	96%	+

 Language impairment	12/21	57%	38/55	69%	+

 Seizure	11/21	52%	32/55	58%	+

 Infantile spasms	0/21	0	0/55	0	+

 Infantile hypotonia	4/21	19%	23/55	41%	+

Growth/Endocrine

 Short stature	5/21	24%	25/55	45%	-

 Local hirsutism	0/21	0	4/55	7%	-

Craniofacial abnormalities

 Coarse face	0/21	0	3/55	5%	+

 Broad forehead	3/21	14%	4/55	7%	+

 Microcephaly	1/21	5%	26/55	47%	+(<2SD)

 Synophrys	2/21	9%	10/55	18%	+mild

 Nasal abnormalities	7/21	33%	35/55	64%	+

 Open mouth	3/21	14%	23/55	42%	+

 Downturned corners of the mouth	3/21	14%	17/55	31%	+

 Macroglossia or protruding tongue	2/21	9%	6/55	11%	-

 Dental abnormalities	4/21	19%	13/55	24%

Skeletal abnormalities	 	 	 	 	+

 Small hands and feet	1/21	5%	23/55	42%	+

 Clinodactyly, 5th finger	2/21	9%	22/55	40%	+

 Brachydactyly	0/21	0	13/55	24%	+

 Short fifth digit of hands/feet	1/21	5%	14/55	25%	+

 Absent hallux	0/21	0	0/55	0	+

Behaviors	 	 	 	 	-

 Autistic feature	13/21	62%	44/55	80%	+

 Sleep disturbance	5/21	24%	17/55	31%	ND

 Self-injurious behavior	2/21	9%	17/55	31%	+

Other	 	 	 	 	-

 Cardiovascular abnormalities	1/21	5%	4/55	7%	-

 Urogenital abnormalities	1/21	45%	1/55	2%	-


	No cancer	Cancer	Total

Mammogram (+)	20	10	32

Mammogram (−)	21	1	21

Total	41	11	52

Measure	Sn = 91 %	Sp = 51 %


HtMM

Normalized jerk

Dominant	Nondominant

Young adults	Middle aged	Senior	All	Young adults	Middle aged	Senior	All

R = 0.75p < 10–6	R = 0.84p < 10–5	R = 0.79p < 10–5	R = 0.80p < 10–17	R = 0.75p < 10–6	R = 0.65p = 0.002	R = 0.67p < 10–3	R = 0.71p < 10–12

Acceleration coefficient of periodicity

Dominant	Nondominant

Young adults	Middle aged	Senior	All	Young adults	Middle aged	Senior	All

R = −0.43p = 0.010	R = −0.63p = 0.004	R = −0.66p < 10–3	R = −0.61p < 10–8	R = −0.61p < 10–3	R = −0.36p = 0.135	R = −0.47p = 0.022	R = −0.51p < 10–5


 	CHD group (n = 45)	Healthy group (n = 15)	P value

Age	59.24 ± 7.87	57.53 ± 4.47	0.304

Gender (male/female)	33/12	7/8	0.058


Predictor	Digit span backward	Letter-number sequencing

	Df	F-value	p-value	η2p	Df	F-value	p-value	η2p

Group	1	0.56	0.46	0.11	1	0.64	0.43	0.10

Score	1	3.45	0.07	0.15	1	7.55	0.01	0.04

Group X Score	1	0.10	0.75	0.00	1	0.82	0.37	0.00

Residuals	33				33


Gene	Disease	Mode of inheritance	Stroke mechanism

GAL	Fabry's disease	X-linked	Large-artery disease and small-vessel disease

NOTCH3	CADASIL	AD	Small-vassel disease

HBB	Sickle-cell disease	AR	Large-artery disease, small-vessel disease, haemodynamic insufficiency

CBS and others	Homocystinuria	AR	Large-artery disease, cardioembolism, small-vessel disease, arterial dissection

mtDNA	MELAS	Maternal	Complex (microvascular and neuronal factors)

FBN1	Marfan syndrome	AD	Cardioembolism and arterial dissection

COL3A1	Ehlers-Danlos syndrome type IV	AD	Arterial dissection

ABCC6	Pseudoxanthoma elasticum	AR	Large-artery disease and small-vessel disease


Fungi	Minimum fungicidal concentrations of ethanol extract of Cleome gynandra in mg/ml	Controls

0.5	0.25	0.125	0.0625	0.0313	0.0156	0.00781	0.00391	−ve ctrl	+ ctrl

Mc	Nfgo	Fgo	Fgo	Fgo	Fgo	Fgo	Fgo	Fgo	Fgo	Nfgo

Tm	Nfgo	Fgo	Fgo	Fgo	Fgo	Fgo	Fgo	Fgo	Fgo	Nfgo

Tr	Nfgo	Nfgo	Nfgo	Fgo	Fgo	Fgo	Fgo	Fgo	Fgo	Nfgo


Testing completed	N (%)

Actionable	92 (65%)

Not actionable or informative	35 (25%)

Informative	11 (8%)

No reportable results	2 (1%)

Test failed	1 (< 1%)


Escala de risco de sangramento RIETE modificada

Variável	Pontos

Hemorragia maior recente (< 1 mês)	2

Creatinina > 1,2 mg/dL	1,5

Anemia	1,5

Câncer	1

Idade > 75 anos	5

Risco baixo: 0; Risco intermediário: 1-4; Risco alto: > 4


	Percentage reporting ‘never’ undertaking measure for reducing risk of violence

	M	F	N	Significance χ2

Check patient notes in advance	52	37	620	p<.001

Leave door ajar when seeing certain patients	80	67	604	p<.001

Accompanied when seeing certain patients	70	64	610	p<.05

Accompanied on visits to certain patients	77	65	610	p<.005

Leaving visit schedule with someone	48	25	618	p<.001

Carry personal alarm	95	77	583	p<.001

Attended self‐defence course	94	85	590	p<.005


Plant Part	Subject of Study	Effect	Reference

ethyl acetate extract of the leaves	lung A549 cancer cells	mitochondrial-mediated apoptosis, cell cycle arrest at G1 phase	[83]

ethyl acetate extract of the leaves	colon HT-29 and HCT-116 cancer cells	mitochondrial-mediated apoptosis, cell cycle arrest at G1 phase, suppression of migration and invasion	[84]

water extract of the leaves	rat’s prostate	reduction of prostate size	[86]

ethanolic extract of the leaves	breast tissues of mice	prevention of DMBA-induced DNA damage	[87]

ethanolic extract of the leaves	DMBA/croton oil induced mice skin papillomagenesis	suppression of tumor initiation and promotion	[88]

ethanolic extract of the leaves	DMH induced colon cancer	reduction of ACF formation	[89]

ethanolic extract of the leaves	K562 chronic myeloid leukemia cells	induction of apoptosis	[85]

leaves boiled in water	metastatic breast cancer	stabilization of disease	[90]

ethyl acetate of the leaves	azoxymethane induced colon cancer	reduction of ACF formation	[91]

ethyl acetate of the leaves	colon HT-29 cancer cells	bioassay-guided isolation of annomuricin E and its apoptosis inducing effect	[91]


Number	Gender	Age	Treatment	Diagnosis of infection	Bacterial etiology	Days of infection detected after TACE and/or RFA	PCT on day of fever	Peak PCT within 7 days	Outcome of infection

1	M	57	TACE	Cholecystitis	Bile, E. hirae	4	2.58	2.58	Cured

2	M	83	TACE	Pneumonia	—	5	0.72	0.72	Cured

3	M	55	TACE	UTI	—	4	0.23	2.40	Cured

4	M	75	TACE	Bacteremia, primary	Blood, E. coli	2	1.55	1.70	Cured

5	M	79	TACE	UTI	—	3	1.19	1.19	Cured

6	M	73	TACE	Pneumonia	Sputum, E. coli	7	0.21	0.24	Cured

7	F	77	Sequential TACE/RFA	Liver abscess	Blood, E. casseliflavus	7	0.16	0.59	Transferred to another hospital

8	M	71	TACE	Bacteremia, cholangitis	Blood, E. gallinarum	1	0.15	0.55	Cured

9	F	65	RFA	Bacteremia, RFA site cutaneous abscess	Blood, S. aureus	1	0.08	0.17	Cured


Type of Gholonj	Traditional term	Type of obstruction	Pathology

Inflammatory Gholonj	Gholonj-e-varami	Non mechanical	Inflammation in the intestinal wall or surrounding organs

Secretory Gholonj	Gholonj-e-balghami	Non mechanical	Accumulation of mucoid Phlegm in lumen of intestine

Flatulency Gholonj	Gholonj-e-reehi	Non mechanical	High gas accumulation in the lumen of intestine

Fecal Gholonj	Gholonj-e-sofli	Mechanical	Accumulation of fecal masses

Parasitic Gholonj	Gholonj-e-doodi	Mechanical	Aggregation of worms in the lumen of intestine

Torsion Gholonj	Gholonj-e-eltevaee	Mechanical	Intestinal torsion or bowel herniation


	E/MPa	μ	α	K/MPa

Theory values	2157	0.2	0.165872	0.875726

Identified values by GA	2135	0.182	0.171365	0.853471

Relative error of computing results for GA (%)	1.02	9	3.31	2.54

Identified values by FGA	2140	0.182	0.168442	0.853532

Relative error of computing results for FGA (%)	0.79	9	1.55	2.54

Identified values by IGA	2143	0.188	0.167812	0.854621

Relative error of computing results for IGA (%)	0.65	6	1.17	2.41


TOOL	COHORT CHARACTERISTICS

 	Disease	Number	Age (years)	Time since diagnosis/transplant	Race & gender	Country of validation

TRAQ [4]	Chronic diseases	192	16-26 (mean: 19.7)	NR	64% white, 56% female	USA

UNCTRxANSITION [17]	Chronic diseases	NR	12-22	NR	NR	USA

Self-management skills assessment guide [16]	Chronic diseases	49	11-19 (mean: 15.6)	NR	86% Caucasian	Canada

SCIS [8]	CF (with pancreatic insufficiency)	76 patients, 70 parents	4-17 (mean: 11.2)	NR	94% white	USA

Readiness questionnaire [9]	CF	36	NR	NR	NR	Canada

RTQ [10]	Renal transplant	48 patients, 32 parents	15-21 (mean: 18.6)	5.73 y	58% white, 29% black, 10% Hispanic	USA

TRS [2]	Liver transplant	71 patients, 58 parents	11-20 (mean: 15.6)	1-19 y (mean: 9.4 y)	56% female	USA

RCBRS [13]	T1DM	69	12-17 (mean: 14.2)	>6 months (mean: 5.49)	87% Caucasian	USA

McPherson et al. [14]	Sickle cell disease	69	14-21	NR	43% female	USA

TRQ [15]	HIV	65	9-25 (mean: 15.8)	1-17 years (mean: 10.5)	44% female, 45% Caucasian	USA


Phase II study

Patient	Treatment group	Visit

BL	C2D1	C3D1	C4D1	D85	D180	D360	ET

1	Lipegfilgrastim	Neg	Neg	Neg	Neg	Pos	NA	NA	NA

2	Lipegfilgrastim	NA	NA	NA	NA	NA	NA	Pos	NA

3	Lipegfilgrastim	Pos	Pos	Pos	Pos	Pos	Pos	Pos	NA

4	Lipegfilgrastim	Pos	Pos	Pos	Pos	Pos	Pos	Neg	NA

5	Lipegfilgrastim	Pos	Pos	NA	NA	NA	Pos	Pos	Neg

6	Lipegfilgrastim	Pos	NA	NA	NA	NA	NA	NA	NA

7	Lipegfilgrastim	Pos	NA	NA	NA	NA	NA	NA	NA

8	Lipegfilgrastim	Pos	NA	NA	NA	NA	NA	Neg	NA

9	Lipegfilgrastim	Pos	NA	NA	NA	NA	NA	NA	NA

10	Pegfilgrastim	NA	NA	NA	NA	Pos	NA	NA	NA

11	Pegfilgrastim	Pos	NA	NA	NA	NA	NA	NA	NA

12	Pegfilgrastim	Pos	NA	NA	NA	NA	NA	NA	NA

Phase III study

Patient	Treatment group	Visit

S	BL	C2D1	C3D1	C4D1	D85	D180	D360

13	Lipegfilgrastim	NA	NA	NA	NA	NA	NA	Pos	Pos

14	Lipegfilgrastim	NA	Pos	Pos	Pos	Pos	Neg	Neg	Neg

15	Lipegfilgrastim	NA	Pos	Pos	Neg	Neg	Neg	Neg	Neg

16	Lipegfilgrastim	NA	Pos	NA	NA	NA	NA	NA	NA

17	Pegfilgrastim	NA	NA	NA	NA	NA	NA	NA	Pos

18	Pegfilgrastim	NA	Pos	NA	NA	NA	NA	NA	NA

19	Pegfilgrastim	Pos	NA	NA	NA	NA	NA	NA	NA

20	Pegfilgrastim	NA	Pos	NA	NA	NA	NA	NA	NA

21	Pegfilgrastim	NA	Pos	NA	NA	NA	NA	NA	NA

22	Pegfilgrastim	NA	Pos	Neg	NA	NA	NA	NA	NA

23	Pegfilgrastim	NA	Pos	NA	NA	NA	NA	NA	NA


Main objectives of participating in the training	n	%

To learn about psychosomatic medicine/biopsychosocial models	28	25%

To learn didactical teaching methods (such as interactive learning and presenting lectures)	23	20%

To acquire practical skills for daily clinical practice (such as communication, role playing, patient interviewing, family interviewing, and creating genograms)	18	16%

To learn about doctor-patient communication skills	12	11%

To improve patient management	9	8%

To learn about the diagnosis and treatment of specific psychosomatic disorders	8	6%

To address administrative and sustainability issues in the curriculum	5	4%

To learn how to use Balint group methods	5	4%

To share experiences with other doctors/acquire more self-experience	4	3%

Other	2	2%


	Intervention, n = 114	Comparison, n = 60

IPV status	n	%	n	%

0	9	8	6	10

3–6	11	10	2	3

≥ 7	93	82	48	80

Missing	1	1	4	7

When partner last inflicted abuse

 Abused in last 12 months(n = 121)

0	1	1	0	0

3–6	3	4	1	2

≥ 7	76	95	39	95

Missing	0	0	1	2

 Abused>12 months ago (n = 33)

0	4	20	3	23

3–6	3	15	0	0

≥ 7	13	65	8	62

Missing	0	0	2	15

 A partner has never abused me(n = 15)

0	4	36	2	50

3–6	2	18	1	25

≥ 7	4	36	0	0

Missing	1	9	1	25

Depressed (EPDS ≥ 13)

No	32	28	26	43

Yes	81	71	33	55

Missing	1		1


Item	Patient Ratings	Clinician Ratings

	Localized	Metastatic	Total	Nurse	Physician	Total

PAIN

 I have pain	2.4	1.8	2.1	3.8	4.0	3.9

 Pain interfered with my daily activities	2.0	1.8	1.9	3.8	3.2	3.5

 I have pain in my back	2.0	1.1	1.5	2.4	2.6	2.5

 I have discomfort or pain in my stomach area	1.7	1.8	1.8	2.6	1.8	2.2

BREATHING

 I have been short of breath	0.7	2.5	1.7	3.8	3.0	3.3

WEAKNESS

 I have felt weak	2.2	2.8	2.5	4.0	3.6	3.8

MOOD

 I worry that my condition will get worse	3.0	3.1	3.1	3.6	2.4	3.0

 I have emotional ups and downs	2.6	2.2	2.4	3.6	1.6	2.6

 I feel depressed	2.6	2.0	2.3	3.6	1.8	2.7

 I am able to enjoy life2	2.2	2.8	2.5	3.8	3.0	3.4

SLEEP

 I have had trouble sleeping	2.5	2.1	2.3	3.6	2.4	3.0

WEIGHT LOSS

 I am losing weight	1.4	2.0	1.7	3.5	3.6	3.6

COGNITIVE

 I have difficulty remembering things	1.6	1.6	1.6	3.5	2.0	2.7

 I have trouble concentrating	1.7	2.1	1.9	3.5	2.0	2.7

FATIGUE

 I feel fatigued	2.3	2.0	2.2	3.8	3.8	3.8

 I have a lack of energy	2.4	2.5	2.5	3.8	3.2	3.4

 I feel tired	2.3	2.1	2.2	3.8	3.0	3.3

 I have trouble starting things because I am tired	1.7	2.1	1.9	3.0	2.0	2.5

 I have trouble finishing things because I am tired	1.9	2.4	2.2	3.0	2.0	2.5

APPETITE

 I have lacked appetite	1.5	1.9	1.7	3.6	3.6	3.6

 I have a good appetite3	2.5	3.1	2.8	3.0	3.4	3.2

INCONTINENCE (BOWEL OR BLADDER)

 I have control of my bowels4	2.4	2.5	2.5	2.2	1.6	1.9

 I have trouble moving my bowels	1.6	1.3	1.5	3.6	2.2	2.9

 I urinate more frequently than usual5	1.7	1.7	1.7	2.2	1.6	1.9

 I have difficulty urinating	1.6	1.2	1.4	2.4	1.6	2.0

OTHER SYMPTOMS

 I have had chills	1.4	1.8	1.6	3.4	2.6	3.0

 I have had fevers	1.3	1.5	1.4	3.8	3.0	3.4

 I have had sweats6	1.2	1.1	1.1	3.8	3.2	3.5

 I feel lightheaded	1.6	1.7	1.6	2.8	2.6	2.7

 I am bothered by blood in my urine7	n/a	n/a	n/a	2.0	2.8	2.4


Target genes	Primers

MMP1	Forward primer: 5′-aagccatcacttaccttgcact-3′

	Reverse primer: 5′-tcagagaccttggtgaatgtca-3′

MMP9	Forward primer: 5′-ctggagacctgagaaccaa-3′

	Reverse primer: 5′-actgctcaaagcctccacaaga-3′

β-Actin	Forward primer: 5′-ctccatcctggcctcgctgt-3′

	Reverse primer: 5′-gctgtcaccttcaccgttcc-3′


Factor	Cronbach’s α	Item-to-subscale correlation	Subscale-to-total correlation

1 Psychological expression	0.92	0.58–0.75	0.92

2 Changes in self and family	0.82	0.49–0.62	0.73

3 Physical symptoms	0.81	0.31–0.64	0.80

4 Social and family connectedness	0.73	0.30–0.73	0.39

5 Fatalism	0.88	0.67–0.84	0.39

6 Religion and faith	0.64	0.17–0.66	0.02

7 Self-query	0.62	0.27–0.47	0.59

8 Coping style	0.59	0.34–0.50	0.12


	Transobturator Sling	Single-Incision Sling	p value

Preoperative daily pads usage (mean)	4.45±0.82 (3-6)	4.25±0.78 (3-6)	p=0.495

Postoperative daily pads usage (mean)	0.30±0.57 (0-2)	0.55±0,68 (0-2)	p=0.192

Postoperatively, the number of patients with	15 / 20	11 / 20	p=0.190

no pad usage (n / all patients)

Subjective cure rates	75%	55%	p=0.190


	Total dust	Respirable crystalline silica dust

Long-term average exposure (mg/m3)

Mean (SD)	6.1 (4.8)	0.27 (0.19)

Median (min.–max.)	4.8 (0–36.7)	0.22 (0–1.16)

Highest exposure ever* (mg/m3)

Mean (SD)	23.5 (11.6)	0.73 (0.34)

Median (min.–max.)	23.8 (0–65.8)	0.74 (0–1.95)

Cumulative exposure (mg/m3-year)

Mean (SD)	226.4 (171.0)	7.32 (5.22)

Median (min.–max.)	183.7 (0–861.7)	6.20 (0–26.6)

Exposure duration (years)

Mean (SD)	27.8 (7.4)

Median (min.–max.)	27.8 (1.1–46.4)


 	Qigong	Exercise therapy	Study population

 	Mean (±SD)	Mean (±SD)	Mean (±SD)

 	N = 10 8 female, 2 male	N = 10 8 female, 2 male	N = 122 107 female, 25 male

Age (years)	40.6 (±10.3)	44.6 (±9.3)	45.6 (±10.7)

VAS baseline (mm)	60.1 (±13.1)	56.5(±12.2)	56.2 (±14.1)

Pain duration (years)	3.9 (±1.2)	3.1 (±1.6)	3.2 (±1.6)


General descriptives	∑ Tot.	Sand	Canopy-forming algae	Seagrass aboveground	Seagrass belowground

Traditional numerical variables

# of species 	36	17	26	29	23

# of species only in one habitat	10	2	4	3	1

# of species found in all habitats	13

Abundance dm-3 (Mean ± SD)		18.4±11.5	2733.8±1624.8	5974.7±4154.3	110.0±44.2

Functional variables

# of modalities expressed (Total)	55	51	55	54	53

# of modalities (Mean ±SD)		44.3±3.1	48.5±1.8	50.6±3.4	51.7±1.1

# of species per modality (Mean)		2.4	3.7	4.5	4.2


 	Shift admitted	p value

 	Day	Night

Mortality (%)	3.5	4.3	0.57

ICU admission (%)	2.2	3.2	0.32

Mean length of stay (days)	5.1	5.7	0.18∗

Readmission, 30 days (%)	8.1	7.1	0.60

Need for surgery (%)	43.5	39.6	0.26


Origin	Region	Isolate serial number	Total number of isolates	Number of genotypes	Number of polymorphic loci	Polymorphic loci (%)

Rich Kser Wallal	Rich Errachidia	7	1	-	-	-

Rich Kser Aït Said	Rich Errachidia	20	1	-	-	-

Rich Kser Tabia	Rich Errachidia	27; 30	2	-	5	13.51

Demnate	Demnate	42	1	-	-	-

Ziz Kser Bouya Jerf	Jerf Erfoud	57-58	2	-	6	16.22

Jerf	Jerf Erfoud	66	1	-	-	-

Erfoud Hay Lagmbita	Jerf Erfoud	76-80; 88	6	6	20	54.05

Erfoud Masoudia	Jerf Erfoud	91-92	2	-	5	13.51

Errachidia Aïne Zerka	Rich Errachidia	116-117	2	-	9	24.32

Toudra Tinghir	Tinghir	119; 121	2	-	14	37.84

Ziz Errachidia	Ziz	122	1	-	-	-

Over all	-	-	21	21	35	94.59


HCC parameters	Number of patients	miR-940 (−)	miR-940 (+)	χ2	P

Gender

 Male	38	31	7	0.515	0.473

 Female	8	5	3

Age

 ≥50 years old	36	29	7	0.080	0.777

 <50 years old	10	7	3

Etiology

 HBV+	38	30	8	0.000	1.000

 HBV−	8	6	2

Cirrhosis

 Positive	37	31	6	1.934	0.164

 Negative	9	5	4

AFP (ng/mL)

 ≥400	29	22	7	0.021	0.885

 <400	17	14	3

Tumor size

 ≥5 cm	26	21	5	0.012	0.913

 <5 cm	20	15	5

TNM stage

 I-II	25	18	7	0.584	0.445

 III-IV	21	18	3

Edmondson grade

 I-II	22	13	9	7.076	0.008∗∗

 III-IV	24	23	1

Tumor microsatellite or multiple tumors

 Yes	20	19	1	4.217	0.040∗

 No	26	17	9

Vascular invasion

 Yes	15	15	0	4.432	0.035∗

 No	31	21	10

Recurrence and metastasis

 Yes	29	26	3	4.313	0.038∗

 No	17	10	7


Target protein or pathway	Drug	CHIKV IC50 (μM)	WST-1 IC50 (μM)	Therapeutic index

Fatty acid synthesis	TOFA	0.15	> 60*	NT

 	Orlistat	0.82	8.67	10.57

 	Cerulenin	3	7.57	2.53

vATPase	Bafilomycin	0.000334	0.003*	NT

CLK1	AnnH18	1.02	9.19	9.04

 	AnnH14	1.55	10.55	6.79

 	KH-CB19	3.36	10.93	3.26

KAT5	(15:3)-Anacardic acid	0.58	2.68	4.65

Calmodulin signalling	TAE684	0.15	2.07	14.28

 	Pimozide	0.28	19.18	69.75

 	Perphenazine	0.63	24.23	38.28

 	6-Hydroxyflavone	2.6	> 60	NT

 	Prenylamine	2.39	16.53	6.91

 	Felodipine	3.24	12.08	3.73

FLT4	Alsterpaullone	0.002	44.38*	NT

 	Pazopanib	0.13	1.32*	NT

 	Axitinib	0.3	0.34*	NT

 	Tivozanib	0.8	8.34*	NT

 	Sorafenib	1.11	18.24	16.42

 	Linifanib	2.15	> 60	NT


Name BRE	5′ primer (5′-3′)	3′ primer (5′-3′)	size (bp)

7–13	GATGAGCTCATGCGAAAGTGAAGGTGGTCCCCAG	TGAAGATCTAGCAAGGAGGAACTGGAGATGTCA	1278

9–13	GAGCTCTCGAACCTCTCTTTCCTATCTC	AGATCTAGCAAGGAGGAACTGGAGATGTCA	695

10–13	GAGCTCTGGAGCTGAGCCTGGAGAGAAG	AGATCTAGCAAGGAGGAACTGGAGATGTCA	530

12–13	GAGCTCTAGGCCATCAGACAGCTCTGAG	AGATCTAGCAAGGAGGAACTGGAGATGTCA	127

9	GAGCTCTCGAACCTCTCTTTCCTATCTC	AGATCTCTTCTCTCCAGGCTCAGCTCCA	189

9–10	GAGCTCTCGAACCTCTCTTTCCTATCTC	AGATCTCCCTCATCTCTCCTTGCAGCT	253

9–11	GAGCTCTCGAACCTCTCTTTCCTATCTC	AGATCTAGGCCCTCAAATTCCTCAGAG	348


Dependent variable	Independent variable	Estimate	Standard error	95% CI	P

SF-BP	Migraine (yes vs. no)	−8.93	1.40	−6.20 to −11.67	<0.001

HAMD (one-point increment)	−1.20	0.10	−1.00 to − 1.40	<0.001

HADS-A (one-point increment)	−0.59	0.19	−0.22 to −0.96	<0.01

Educational years (one-year increment)	0.90	0.29	1.47 to 0.32	<0.01

PS	Migraine (yes vs. no)	1.33	0.23	1.78 to 0.89	<0.001

HAMD (one-point increment)	0.19	0.02	0.22 to 0.16	<0.001

HADS-A (one-point increment)	0.12	0.03	0.18 to 0.06	< 0.001

Educational years (one-year increment)	−0.13	0.05	−0.03 to −0.23	0.01

Married (yes vs. no)	0.53	0.21	0.95–0.12	0.01

Age (one-year increment)	0.03	0.01	0.05 to 0.004	0.02

Anxiety disorders (yes vs. no)	0.52	0.24	1.00 to 0.05	0.03


Coal samples	Atomic concentration of elements/%	(O/C) ratio/%

C 1s	O 1s	N 1s	S 2p	Elemental analysis	XPS analysis

Beizao lignite	80.34	18.22	1.44	/	20.61	22.68

Daliuta long flame coal	84.37	14.17	0.94	0.52	16.02	16.80

Yushuwan gas coal	87.68	11.5	0.82	/	12.03	13.12

Xinjulong fat coal	89.11	8.88	1.72	0.29	7.15	9.97

Wugou coking coal	88.41	9.08	1.83	0.68	5.50	10.27

Yangquan anthracite	89.18	9.05	1.34	0.43	2.52	10.15


Variable	N	R Pearson Correlation	Level of significance

Organizational culture and organizational commitment	165	0.419	0.027


RSV	Influenza A (H1N1) virus

Age <6 months	Age <5 years

History of prematurity	Chronic lung disease

Chronic lung disease	Congenital heart disease

Congenital heart disease	Immunocompromised conditions

Viral coinfection


Sensory neurons in the DRGs	BL40	GB30

Large-sized neuron	58 (10.78%)	149 (17.21%)

Medium-sized neuron	222 (41.26%)	357 (41.22%)

Small-sized neuron	258 (47.96%)	360 (41.57%)


		Number	Percent

Gender	Female	379	90.9

Male	38	9.1

Country	Australia	396	94.9

New Zealand	21	5.1

Age (years)	21-30	23	5.5

31-40	84	20.1

41-50	156	37.4

51-60	141	33.8

60+	13	3.1

Length of Time Working in Haemodialysis	<1 year	11	2.6

1-2 years	22	5.3

3-5 years	70	16.8

6-10 years	116	27.8

11-15 years	94	22.5

16-20 years	41	9.8

>20 years	63	15.1

Nursing Classification	Registered Nurse (RN)	406	97.4

Enrolled Nurse (EN)	11	2.6

Highest Nursing Qualification	Certificate in Nursing	85	20.4

Diploma in Nursing	56	13.4

Undergraduate Degree	74	17.7

Postgraduate Certificate/Diploma	170	40.8

Masters/Doctorate	32	7.7

Work Location	Metropolitan	177	42.4

Regional	144	34.5

Rural	85	20.4

Remote	11	2.6

Type of Unit	In-Center	187	44.8

Satellite	202	48.4

Home	28	6.7


Inclusion criteria	Exclusion criteria

Women < 40 years old	Women who conceived the fetus using artificial methods including in-vitro fertilization or intrauterine insemination

Aboriginal ancestry	Women carrying more than one fetus

Pregnant with singleton	Surrogate mothers

 	Women who suffer from severe chronic medical conditions including active cancer, severe infectious diseases including HIV, hepatitis B or C, or who are VDRL positive


Variable	Points

Age >80 years	1

History of cancer	1

History of heart failure or chronic lung disease	1

Pulse rate ≥110 bpm	1

Systolic blood pressure <100 mmHg	1

Oxygen saturation <90 % on room air	1


	Description of framework objectives

1.	Surveillance to develop shared operational definitions and determinants of mental illness

2.	Epidemiological research into determinants and protective factors for mental health and their relationships to chronic diseases

3.	Prevention research to determine the importance of mental illness/health as factors in public health promotion and prevention

4.	Communication to develop culturally, linguistically, and developmentally appropriate educational products

5.	Education of Health Professionals including the development of appropriate education plans for professional audiences

6.	Program Integration Support at various jurisdictional levels

7.	Policy Integration that involves the development of policies at all government levels for all audiences and stakeholders

8.	Systems to Promote Integration such as establish systems integration to promote program and policy integration across multiple infrastructures


Outcome	Regression coefficient(95%CI)

Publication year	Type of fractures

Blood loss	− 0.02 (− 0.11, 0.08)	− 0.70 (− 2.04, 0.64)

Operation time	− 0.32 (− 0.10, 0.04)	− 0.22 (− 1.28, 0.83)


Scale	Fatigue description

1	No such feeling

2	Negligible feeling

3	Some feeling

4	Clear feeling

5	Strong feeling

6	Very strong feeling

7	Extremely strong feeling


C/N0	25 dB-Hz	30 dB-Hz	35 dB-Hz	40 dB-Hz

Standard Receiver	Optimal Bandwidth	15 Hz	22 Hz	28 Hz	35 Hz

Tracking Error of the PLL in Optimal Bandwidth	28 deg.	15 deg.	9 deg.	7 deg.

Dynamic Stress Noise Proportion (BPLL = 20 Hz)	8%	14%	21%	28%

Ultra-tightly Integrated GNSS/INS Receiver	Optimal Bandwidth	7 Hz	9 Hz	13 Hz	25 Hz

Tracking Error of the PLL in Optimal Bandwidth	20 deg.	12 deg.	8 deg.	6 deg.

Dynamic Stress Noise Proportion (BPLL = 20 Hz)	<1%	<1%	<1%	<1%


Characteristic	Number (%)

Male (n = 412)	220 (53)

Role in ED (n = 419)

 Attending	207 (49)

 Resident	170 (41)

 Advanced practice provider	42 (10)

Years working in ED (n = 417)

 < 1 year	52 (13)

 > 1 – < 5 years	164 (39)

 > 5 – < 10 years	53 (13)

 > 10 – < 20 years	85 (20)

 > 20 years	63 (15)

Location of ED* (n = 420)

 Rural	8 (2)

 Suburban	24 (6)

 Urban	410 (98)

ED practice setting* (n = 420)

 Academic	409 (97)

 Community	71 (17)

 VA/military	16 (4)

Prior therapeutic OA use (n=420)	265 (63)